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Ketamine Psychedelic Psychotherapy:
Focus on its Pharmacology, Phenomenology, 
and Clinical Applications
Meant to be an authoritative guide for psychiatrists and others interested in understanding and 
applying ketamine psychedelic psychotherapy (KPP), this paper focuses on its pharmacology, 
phenomenology, and clinical applications. Ketamine is a dissociative anesthetic widely used by 
physicians and veterinarians in the United States. In addition to its anesthetic and dissociative 
properties, ketamine also has a multitude of other psychological and pharmacological properties, 
which include analgesic, sedative, neuroprotective, anxiolytic, antidepressant, stimulant, euphoriant, 
and hallucinogenic effects. The literature on the clinical application of KPP is comprehensively 
reviewed, practical advice for using KPP is given, and the pharmacology and phenomenology of 
ketamine-induced psychedelic experiences are explored, including in relationship to transpersonal 
healing and possible iatrogenic consequences of misuse of KPP. 
, 33(2), 2014, pp. 84-140 
Ketamine is an extremely interesting substance, especially from a transpersonal healing perspec-tive, as it not only has a wide range of potential 
clinical applications, including through what is here 
called ketamine psychedelic psychotherapy (KPP), but 
it is the only legally-available (i.e., through a physician’s 
off-label prescription without having to go through 
regulatory hurdles) substance within the United States 
that can reliably produce psychedelic experiences. 
Consequently, we review the literature on the clinical 
application of KPP, and focus on the phenomenology 
of ketamine-induced psychedelic experiences in terms 




The arylcyclohexylamines (also known as arylcyclo-hexamines or arylcyclohexanamines) were originally 
developed as anesthetics by Parke-Davis. Unlike all 
other anesthetic agents, except perhaps nitrous oxide, 
the arylcyclohexylamines do not generally extinguish 
consciousness, but instead appear to “dissociate” mind 
from body (thus the name of “dissociative anesthetics”). 
The arylcyclohexylamines predominantly block the 
N-methyl-D-aspartate (NMDA) receptor, a target for 
the neurotransmitter glutamate in the brain, and prevent 
the NMDA receptor from being activated by glutamate 
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Hajikhani, & Naserbakht, 2011). In addition to NMDA 
antagonism, the arylcyclohexylamines produce µ opioid 
receptor agonism (Itzhak & Simon, 1984) and cause 
dopamine reuptake inhibition (Chaudieu et al., 1989). 
Some of the arylcyclohexylamines also produce sigma 
receptor agonistic (He et al., 1993), nACh receptor 
antagonistic (Eterović et al., 1999), and D2 receptor 
agonistic (Seeman, Ko, & Tallerico, 2005) actions. 
Antagonism of the NMDA receptor generates 
dissociative (hallucinogenic), anesthetic, neuroprotective 
and anticonvulsant effects; stimulation of the sigma 
and D2 receptors contributes to hallucinogenic 
(psychomimetic) effects; activation of the µ-opioid 
receptor causes analgesic and anxiolytic effects; blockade 
of the dopamine transporter mediates stimulant and 
euphoriant effects (as well as adding to psychomimetic 
effects in higher doses); the combination of the two last 
qualities confers a strong antidepressant effect; and the 
combination of all the above pharmacological properties 
make the arylcyclohexylamines powerful psychedelic 
drugs.
The first member of the arylcyclohexylamine class 
to be discovered was phencyclidine. It was synthesized in 
1926, eventually patented in 1953 by the Parke-Davis 
pharmaceutical company for use as an anesthetic agent 
for humans and animals, and was marketed under the 
brand name Sernyl® (referring to serenity). By 1965, its 
use with humans was discontinued as clinical studies 
revealed that patients experienced what was then seen as 
“psychotic” symptoms when emerging from the drug’s 
effects (so-called “emergence delirium”). Today, it is 
rarely used even in the veterinary community. However, 
it continues to be legally available for research purposes 
in the United States, but as a Schedule II controlled 
substance.
Phencyclidine re-emerged as a drug of abuse 
in the mid-1960s due to its strong euphoriant and 
psychedelic qualities. The drug was relatively easy and 
inexpensive to manufacture in clandestine laboratories 
and it quickly became popular on the streets, with names 
such as “Angel Dust” and PCP.  PCP can be pressed into 
pills or put in capsules and swallowed. When ingested 
orally, effects are felt in 30 to 45 minutes and last from 6 
to 24 hours.
 
Doses of less than 5 mg produce euphoriant 
effects (feelings of elation and joy, relaxation, feelings of 
unreality and mild dissociation from the environment), 
while doses of 10 mg or more produce psychedelic effects 
(distorted sense of one’s body, a feeling of weightlessness, 
distorted sense of time and space, visual and auditory 
hallucinations). 
PCP use spread in the 1970s. When PCP is 
snorted or smoked (for example, users dipped tobacco 
or cannabis cigarettes in the liquid form of PCP or 
sprinkled its powder form on a leafy material like 
tobacco or cannabis), the effects are felt within 4 to 5 
minutes and last from 4 to 6 hours. PCP can also be 
injected, although this appears to be a less common 
route of administration. 
 PCP use may have peaked around 1978, when 
People magazine called it the country’s “number one” 
drug problem. PCP became infamous for its recurrent 
binges (so-called “runs”), when chronic users would 
take PCP repeatedly for 2 to 3 consecutive days at a 
time without eating or sleeping. It was estimated that 
at least 7 million Americans used PCP on at least 
one occasion between 1975 and 1983. The American 
Psychiatric Association (APA) Diagnostic and Statistical 
Manual (DSM)-IV-TR (APA, 2000) devoted a separate 
chapter to this substance entitled Phencyclidine-Related 
Disorder. By the mid-1980s, PCP use began declining, 
perhaps partly as a result of the increased popularity of 
ketamine and crack cocaine. Eventually, PCP use slowly 
faded away, although there is still some manufacture 
by clandestine chemists. Today PCP is classified as a 
hallucinogen and the new APA (2013) DSM-5 places its 
effects in the Hallucinogen-Related Disorder category, 
with classical hallucinogens. 
 The second compound from the arylcyclo-
hexylamines class, eticyclidine, was also developed by 
Parke-Davis and evaluated for anesthetic potential 
under the code name CI-400. Eticlydine is very similar 
in effects to phencyclidine and is slightly more potent. 
Parke-Davis did not continue its research of eticyclidine 
after the development of ketamine, a similar drug with 
more favorable properties. Nevertheless, eticyclidine 
(under the name of PCE) did make its way to the 
streets and was briefly abused in the 1970s and 1980s. 
It did not become popular with recreational users due 
to its unpleasant taste and tendency to cause nausea. 
Eticyclidine was placed into the U.S. Schedule I list of 
illegal drugs in the 1970s and its use is unknown today.
 Ketamine was the third compound from the 
class of arylcyclohexylamines that Parke-Davis developed 
as part of an effort to find a safer and more predictable 
anesthetic agent than its precursors. Unlike the first 
two creations of Parke-Davis, ketamine proved to be 
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the most promising compound and eventually became 
the company’s most successful anesthetic, sedative, 
analgesic, anxiolytic, and neuroprotective agent. 
Ketamine Pharmacology
Ketamine hydrochloride, a phencyclidine derivative, was originally invented in 1962 by the American 
organic chemist Calvin Stevens, who initially 
called the compound CI-581 and later renamed it 
ketamine. Ketamine, like all the arylcyclohexylamines, 
predominantly targets the neurotransmitter glutamate, 
which is an excitatory messenger that turns on the 
brain cells and triggers an electrical impulse. Ketamine 
opposes this action by blocking the N-methyl-D-aspartate 
(NMDA) receptor. It prevents the NMDA receptor from 
being activated by glutamate (Anish, Berry, Burton, & 
Lodge, 1983; Thomson, West, & Lodge, 1985). Ketamine 
also has direct and/or indirect effects on the µ opioid 
(Fink & Nagai, 1982; Fidecka, 1987; Freya, Latish, 
Schmidhammer, & Portoghese, 1994; Herman, Vocci, & 
Bridge, 1995; Latasch & Freye, 1993; Smith et al., 1980; 
Winters et al., 1988), dopamine (French, Mura, & Wang, 
1993; Irifune, Shimizu, & Nomoto, 1991; Irifune et al., 
1997; Keita, Lecharny, Henzel, Desmonts, & Mantz, 
1996; Nishimura & Sato, 1999; Rao, Kim, Lehmann, 
Martin, & Wood, 1990), serotonin (Kim, Park, & Park, 
1998; Lindefors et al., 1997; Martin, 1982; Minami, 
Minami, & Harris, 1997; Pallotta, Segieth, & Whitton, 
1998), acetylcholine (Cohen, Chan, & Trevor, 1973; 
Durieux & Nietgen, 1997; Mimura et al., 1992; Morita 
et al., 1995; Toro-Matos, Rendon-Platas, Avila-Valdez, 
& Villarreal-Guzman, 1980), GABA (Drejer & Honore, 
1987; Lindefors et al., 1997), cannabinoid (Richardson, 
Aanonsen, & Hargreaves, 1998; Stella, Schweitzer, & 
Piomelli, 1997), nitric oxide (Abajian, Page, & Morgan, 
1973; Carroll, Lac, Asencio, & Kragh, 1990; Galley & 
Webster, 1996; Lin, Chiou, & Wang, 1996) and sigma 
(Hustveit, Maurset, & Oye, 1995) systems.
 Ketamine hydrochloride may be administered 
via a variety of routes including oral, sublingual, rectal, 
intranasal, intramuscular, and intravenous routes. 
Ketamine is a highly lipid soluble chemical and, as a 
result, its clinical effects present within 45 to 50 seconds 
of administration when given intravenously, within 
3 to 4 minutes when given intramuscularly, within 
5 to 10 minutes when given intranasally, and within 
20 to 30 minutes when given orally (Alonso-Serra & 
Wesley, 2003). The 1992 version of the Physicians’ Desk 
Reference (PDR) indicated that ketamine use is usually 
devoid of life-threatening side-effects and that several 
instances of unintentional administration of overdoses 
of ketamine of up to ten times that usually required for 
surgical anesthesia have been followed by prolonged but 
complete recovery (PDR Network, 1992). 
 More than 10,000 published reports describe 
ketamine’s high level of effectiveness and its confirmed 
biological safety in most cases, although like all drugs 
there is the possibility of some adverse effects in some 
people (Bauman, Kish, Baumann, & Politis, 1999; Dachs 
& Innes, 1997; Ersek, 2004; Reich & Silvay, 1989; Ross 
& Fochtman, 1995; Shapiro, Wyte, & Harris, 1972). 
Clinical studies have generally detected no long-term 
impairment of behavior or personality functioning as 
a result of repeated ketamine use (Siegal, 1978), but 
some individual case studies of ketamine dependence 
have raised questions at times (e.g., Jansen 1990, 2000, 
summary in Jansen 2001) and there have been some 
recent concerns about, for example, toxicity to the urinary 
system (e.g., Selby et al., 2008; Wood, 2013.)
 According to several in vitro and animal studies, 
ketamine can even have neuroprotective properties under 
some circumstances (Hoffman et al., 1992; Shapira, 
Artru, & Lam, 1992; Shapira, Lam, Eng, Laohaprasit, 
& Michel, 1994). Subsequently, ketamine has been used 
as a neuroprotective agent to prevent brain damage from 
head trauma, strokes, heart attacks, epileptic seizures, low 
oxygen levels, and low blood-sugar levels (Albanese et al., 
1997; Bar-Joseph, Guilburd, Tamir, & Guilburd, 2009; 
Filanovsky, Miller, & Kao, 2010; Hirota & Lambert, 
1996; Hughes, 2011; Mayberg, Lam, Matta, Domino, & 
Winn, 1995; Rothman et al., 1987; Shapira et al., 1994; 
Weiss, Goldberg, & Choi, 1986).
Ketamine Biochemistry 
and Electrophysiology
Extensive research of the biochemical aspects of ketamine has been done by one of us, a Russian 
researcher, Evgeny Krupitsky, and a U.S. researcher, John 
Krystal, who both have conducted extensive independent 
studies since the 1980s. Krupitsky and Krystal later 
collaborated in researching the biochemistry of ketamine 
(Krupitsky et al., 2001; Krystal et al., 2003a). 
 Krupitsky conducted ketamine studies at the 
Center for Research in Addiction and Psychopharma-
cology in St. Petersburg, Russia, researching the effects 
of ketamine administration on metabolism of biogenic 
amines, including dopamine, serotonin, monoamine 
oxidase type A (MAO-A), monoamine oxidase type B 
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(MAO-B), GABA, ceruloplasmin, and B-endorphin. 
The results of these biochemical investigations show 
that during the ketamine session, dopamine lev els were 
increased, serotonin and GABA concentrations were 
not altered significantly, ceruloplasmin activity and the 
B-endorphin levels were increased, and the activity of 
MAO-A in blood serum and MAO-B in blood platelets 
significantly decreased. The results provided biochemical 
data showing that the pharmacological actions of 
ketamine affect monoaminergic and opioidergic 
neurotransmitter metabolism (Krupitsky et al., 1990).
 These changes in the metabolism of 
neurotransmitters allow some opinions to be formed 
about the underlying neu rochemical mechanisms of 
ketamine’s psychedelic action. For example, an increase 
of cerulo plasmin activity causes a corresponding increase 
in the conversion of monoamines into adrenochromes, 
which have hallucinogenic activity (Anokhina, 1975; 
Nalbandyan, 1986). This particularly takes place under 
the conditions of inhibited MAO activity and increased 
dopamine levels. This is of interest because such 
conditions are typical for the action of many classical 
hallucinogens (Hamox, 1984; McKenna, Towers, 
& Abbott, 1984). The fact that the pharmacological 
actions of ketamine affected both monoaminergic and 
opioidergic systems, two neurochemical systems involved 
in pathogenesis of alcoholism, is an important result of 
this biochemical investigation, as it is possible that these 
actions contribute to the efficacy of KPP.
Krupitsky has also used EEG computer-assisted 
data in studying underlying mechanisms of KPP 
(Krupitsky & Grinenko, 1997). EEG recordings were 
taken before, during, and after the ketamine session 
by placing 16 electrodes according to the international 
scheme. After analog-digital conversion, standard 
programs of computer assisted spectral EEG analysis 
and topographic mapping of EEG were employed. The 
data of EEG computer-assisted analysis demonstrated 
that ketamine increases delta activity (1.5 – 2X) and 
particularly theta-activity (3 – 4X) in all regions of 
the cerebral cortex. This is evidence of limbic system 
activation during ketamine sessions, as well as evidence 
of the reinforcement of the limbic cortex interaction 
(Pribram, 1971). These find ings can also be considered to 
a certain extent as indirect evidence of the strengthening 
of the interactions between the so-called conscious and 
unconscious levels of the mind during KPP (Simonov, 
1987).
 There are also some data indicating that the 
interac tion between the frontal cortex and the limbic 
system are important for the action of ketamine on the 
brain. Previously, it has been demonstrated in positron 
emission tomography (PET) with fluorodeoxyglucose 
(FDG) studies that ketamine-induced disturbances of 
glutamatergic neurotransmission results in a specific 
hyperfrontal metabolic pattern in the human brain 
associated with psychedelic experiences, specifically 
visionary experience and ego-dissolution (Vollenweider 
et al., 1994). Also, frontal lobotomy reduces the 
psychedelic response to phencyclidine in schizo-
phrenic patients (Itil, Keskiner, Kiremitci, & Holden, 
1967). Ketamine activates the interaction between 
brain structures associated with cogni tive processing 
of information (frontal cortex) and structures involved 
in the processes of emotions, motivations, memory, 
and subconscious experiences and perceptions (limbic 
struc tures). Such enhanced interaction may be an 
important neurophysiological mechanism underlying 
the phenomenol ogy of ketamine psychedelic experiences 
and the dramatic psychological changes caused by those 
experiences.
 John Krystal, chair of the department of 
psychiatry at Yale University School of Medicine, directed 
ketamine research at the Connecticut Mental Health 
Center in New Haven. He utilized ketamine primarily 
as a psychomimetic agent to study the neurobiology of 
schizophrenia, and focused on ketamine’s effects on 
perceptual and cognitive functioning (Krystal et al., 
1994, 1998a, 1998b, 1999, 2000). Krystal’s group also 
collected a substantial body of evidence demonstrating 
that ketamine’s major underlying mechanism of action 
on the brain is the blockade of the N-methyl-D-asparate 
(NMDA) receptors, which are mostly located in the 
cortex and hippocampus and are involved in processes of 
integration and transmission into the cortex of incoming 
signals from all sensory modalities (Krystal et al., 
1994). This finding was confirmed by another group of 
investigators (Oye, Paulsen, & Maurset, 1992), verifying 
that a significant reduction of sensory transmission and 
activation of autonomous cortex-limbic interactions may 
be important underlying mechanisms of the psychedelic 
action of ketamine.
 In addition, Krystal’s group completed clinical 
research studying the effect of ketamine’s NMDA 
glutamate receptor antagonist response in recovering 
ethanol-dependent patients (Krystal et al., 1998b). 
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Twenty male patients with alcoholism who had not 
consumed alcohol for 10 days to 4 weeks prior to the study 
completed 3 test days that involved the administration of 
very low (0.1 mg/kg) and low-to-medium (0.5 mg/kg) 
doses of ketamine or saline solution under randomized 
double-blind conditions. Ethanol-like subjective effects 
were assessed using visual analog scales to measure 
“high” and degree of similarity to ethanol, cocaine, and 
cannabis, and also employed a scale assessing the number 
of standard alcohol drinks producing similar subjective 
effects. This team concluded that ketamine produced 
ethanol-like effects in a dose-related way on each scale, 
exhibiting similarity to ethanol. However, its effects 
were judged more similar to the sedative, rather than 
stimulant, alcohol effects. Ketamine effects also were 
more like ethanol than cannabis or cocaine. Ethanol-
like effects were more prominent at the higher ketamine 
dose, a dose rated as similar to greater levels of ethanol 
intoxication. The production of ethanol-like subjective 
effects by ketamine supports the potential clinical 
importance of NMDA receptor antagonism among the 
mechanisms underlying the subjective effects of ethanol 
in humans (Krystal et al., 1998b; Krystal et al., 2003b). 
Ketamine Development
In 1964, ketamine was officially tested on the first human subjects, the inmates at the Jackson Prison in 
the State of Michigan. The study was done by Edward 
Domino, MD, an American clinical pharmacologist 
(Domino, Chodoff, & Corssen, 1965). Domino was the 
first investigator to discover that ketamine has multiple 
pharmacological effects, including anesthetic, analgesic, 
and antidepressant effects.  
 Domino was also the first researcher who 
discovered the “schizophrenomimetic” (hallucinogenic) 
properties of ketamine. He reported that most of his 
subjects described strange experiences like feeling 
“spaced out” and “floating” (Domino, 2010). Initially, 
Domino used the word “dreaming” to describe the 
drug’s hallucinogenic effect. However, the Parke-Davis 
scientists did not like that name out of the company’s 
concerns that the U.S. Food and Drug Administration 
(FDA) may label ketamine as “psychotomimetic,” which 
might stop the clinical development of a very promising 
pharmaceutical. Domino discussed the unusual actions 
of ketamine with his wife and mentioned that the 
subjects were “disconnected” from their environment. 
His wife came up with the term “dissociative anesthetic” 
that “dissociates” so-called mind from body (Domino, 
2010). From that time, the “dissociative anesthetic” 
name has been assigned not only to ketamine 
hydrochloride, but also to the entire class of psychoactive 
arylcyclohexylamines.
 In 1966, Parke-Davis patented ketamine under 
the brand name Ketalar for use as an anesthetic in 
humans and animals. Ketamine was successfully tried 
on American soldiers in the Vietnam War (when it 
got nicknamed the “buddy drug” because it could be 
administered by a corpsman or a fellow soldier due to its 
relative safety and ease of administration). In the course 
of the Vietnam War, it became the most widely used 
battlefield anesthetic, sedative, and analgesic, giving an 
excellent opportunity for American anesthesiologists 
and surgeons to become familiar with the agent.  
 Ketamine rapidly became the drug of the choice 
used by the U.S. military for CASEVAC, a military term 
for the emergency patient evacuation of casualties from 
a combat zone to a clearing station or a nearby hospital, 
increasingly by helicopter in the jungle wars. In most 
cases a wounded soldier would be in a hospital receiving 
medical care within 35 minutes of being wounded. 
Patients were moved directly from the battlefield directly 
into the preoperative and resuscitation shelter while 
under the effects of field-administered ketamine. 
 Impressively, the use of ketamine as an agent 
for analgesia and conscious sedation during battlefield-
casualty evacuations helped to decrease the mortality rate 
of wounded soldiers who made it to medical treatment 
from 4.5% during the Korean War to 2.6% during the 
Vietnam War. The U.S. soldiers knew that, if they were 
wounded, they had a better chance of surviving and 
quickly receiving medical care than in any other war 
in which the United States had previously participated, 
a fact that did much to boost troop morale (Vietnam 
Studies, Department of the Army, 1973).
 Eventually, in 1970, the FDA approved the use 
of ketamine anesthesia with children, adults, and the 
elderly. Since that time, ketamine has been widely used in 
hospitals and for office procedures due to its rapid onset, 
short duration of action, and superior safety. Ketamine 
has now been in clinical practice for 50 years and has 
been continually used as a usually very safe anesthetic 
to evoke general anesthesia, a first line agent to induce 
procedural conscious sedation, a potent non-opiate 
analgesic to control both acute and chronic pain, a unique 
neuroprotective agent to prevent brain damage, a superior 
anxiolytic to control preoperative and end-of-life anxiety, 
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a rapid-onset antidepressant to treat chronic depression 
and other treatment-resistant psychiatric conditions, and, 
for a period, the only legal hallucinogenic drug available 
to conduct psychedelic psychotherapy (although there 
has been some forward movement in that regard in recent 
years, with some work recommencing using substances 
such as psilocybin and DMT; Friedman, 2006). 
 Unsurprisingly, ketamine has also become 
popular on “the streets” for its strong euphoriant effects 
and potent hallucinogenic properties. There are some 
matters of relevance to therapeutic issues to be learned 
from its non-medical and “recreational” use, so this 
paper also reviews some of that material.
Ketamine Pharmacotherapy
It has been proposed (Haas & Harper, 1992; White, Way, & Trevor, 1982) that the “ideal” agent for anesthesia 
must possess the following specific characteristics:
• Effective in inducing anesthesia
• Minimal cardiovascular effects
• Minimal respiratory effects
• Ability to titrate
• Rapid onset of action
• Predictable duration of effect
• Short elimination half-life
• Anxiolytic at sub-anesthetic doses
• Analgesic in sub-anesthetic doses
• Soluble in water
• Stable in solution
• Absence of pain on injection
• Absence of post-injection irritation.
A few classes of drugs, such as the opioids, barbiturates, 
and benzodiazepines, meet some, but not all, of these 
criteria. Today, ketamine is one of only a very few agents 
that regularly meets all of these criteria of an ideal 
anesthetic, when the dose is suitable for the patient and 
purpose. Certainly a large bolus dose of ketamine as 
a sudden intravenous push can affect respiration and 
intracranial pressure, but in that instance it can often be 
argued that the dose was not suitable for the patient and 
purpose. Ketamine is included in the 18th edition of the 
World Health Organization (2013) model list of essential 
medicines, promulgating its availability in a health system.
It has been a half a century since Domino 
administered ketamine to the first human subjects 
(Domino et al., 1965). Since then, ketamine has 
become widely accepted as an outstanding agent to 
reduce preoperative anxiety and facilitate induction of 
general anesthesia, as it appears to have virtually all of 
the desired properties of the ideal agent.  Subsequently, 
ketamine has been used worldwide for an extensive range 
of various procedures, including preoperative sedation, 
intraoperative anesthesia, and postoperative analgesia 
(Haas & Harper, 1992). 
 While there are many anesthetic drugs available, 
internationally ketamine remains amongst the most 
popular general anesthetics, especially in the Developing 
World and emergency contexts, because of its low cost, 
ease of storage, advantageous airway and respiratory 
properties, hemodynamic stability, broad range of 
clinical applications, and excellent therapeutic index 
(Craven, 2007; USAARL Report, 2010). Ketamine’s 
wide-therapeutic window (Green, Clem, & Rothrock, 
1996; Green et al., 1999; Strayer & Nelson, 2008) 
makes it the anesthetic of choice in austere or resource-
poor environments where monitoring equipment 
may be rudimentary or absent and a single operator 
must provide the anesthetic and monitor a patient 
(Green et al., 1996; Strayer & Nelson, 2008). It can be 
administered via almost any route, although intravenous 
(IV) and intramuscular (IM) administrations are by far 
the most popular and best studied for surgical anesthesia 
(Mistry & Nahata, 2005). The initial dose of ketamine 
administered intravenously ranges from 1 mg/kg – 4.5 
mg/kg, and intramuscular doses range from 6.5 – 13 mg/
kg (White et al., 1982). Ketamine is highly lipid soluble 
and, as such, clinical effects present within one minute 
of administration when given intravenously and within 
five minutes when given intramuscularly (Alonso-Serra 
& Wesley, 2003). 
Today, the most frequent use of ketamine has 
been for conscious sedation for physically or emotionally 
painful procedures (procedural sedation) and analgesia 
for acute and chronic pain, both on the battlefield 
and in emergency departments worldwide, and also in 
vetinary medicine. For use in sedation only, the doses 
of ketamine are 0.5 – 0.75 mg/kg IV or 2 – 4 mg/kg 
IM; for use as an analgesic and/or anxiolytic agent, the 
doses of ketamine are 0.2 – 0.3 mg/kg IV, 0.5 – 1.5 mg/
kg IM and intranasal, and 1 – 2 mg/kg sublingual, oral 
and rectal. 
 Peak plasma concentrations have been reported 
to occur within 1 min following IV administration, 
5 to 15 minutes following IM injection, 30 minutes 
after oral administration and 45 minutes after rectal 
administration (Domino et al., 1984; Grant, Nimmo, 
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& Clements, 1981; Pedraz et al., 1989). Elimination is 
primarily by the kidney, and only a small percentage is 
recovered in the urine as the unchanged drug (Chang, 
Savory, & Albin, 1970). The elimination half-life of 
ketamine is approximately 2 hours (Domino et al., 1984), 
although there are some longer estimates. Metabolites 
which are also active NMDA receptor blockers can 
sometimes be detected in urine for up to a week or more 
(e.g., Ebert, Mikkelsen, Thorkildsen, & Borgbjerg, 1997.)
 When ketamine is administered in small 
(analgesic, anxiolytic, and sedative) doses, it does not 
usually impair spontaneous respirations and does not 
increase blood pressure and heart rate (Subramaniam, 
Subramaniam, & Steinbrook., 2004; Visser & Schug, 
2006; White et al., 1982), which makes ketamine an 
especially desirable analgesic/anxiolytic/sedative for 
use on the battlefield and in evacuation procedures. 
Today, combat medics continue using ketamine for 
battlefield sedation and pain management because of its 
minimal impact on medic carrying capacity and ability 
to withstand environmental extremes. It is also much 
more field expedient than any other analgesic due to 
its low occurrence of side effects (Guldner, Petinaux, 
Clemens, Foster, & Antoine, 2006). In a recent review of 
analgesic options for pain relief on the battlefield, Black 
and McManus (2009) wrote that, in sub-anesthetic doses, 
ketamine is almost ideal as an analgesic due to providing 
profound-pain relief, potentiating opioids, preventing 
opioid hyperalgesia, and its margin of safety.
The use of ketamine by emergency physicians 
prior to the 1990s was infrequent (Green & Krauss, 
2004a, 2004b). However, after a landmark study by 
Green and Johnson (1990), it has become one of the most 
popular agents for procedural sedation and analgesia 
in emergency departments. In their review of 11,589 
administrations of ketamine for sedation, Green and 
Johnson (1990) firmly established the drug’s safety and 
efficacy for medical use. 
 Since then, ketamine has been extensively used 
as an analgesic in intensive and acute care medicine 
(particularly in emergency medicine), and there has 
been considerable further research on the efficacy, safety, 
contraindications, guidelines, and dosing of ketamine 
(Green & Krauss, 2004a, 2004b; Lin & Durieux, 2005; 
Mistry & Nahata, 2005). It has been well documented 
that ketamine has a very low frequency of adverse effects 
in doses used for conscious sedation and analgesia 
(Alonso-Serra & Wesley, 2003; Cherry, Plummer, 
Gourlay, Coates, & Odgers, 1995; Howes, 2004; 
Jennings, Cameron, & Bernard, 2011; Porter, 2004). 
Today ketamine is routinely stocked in all emergency 
departments across the United States, Australia, New 
Zealand, and many other countries (Sacchetti, Senula, 
Strickland, & Dubin, 2007); due to its exceptional 
analgesic and sedative properties at low doses, ketamine 
has been widely used for treatment of acute postoperative 
pain, so-called breakthrough pain in patients with acute 
and/or chronic pain, and for management of neuropathic 
pain disorder, ischaemic limb pain disorder, refractory 
cancer pain, and as a pediatric sedation tool for use with 
acutely injured children (Bell, Dahl, Moore, & Kalso, 
2006; Buvanendran & Kroin, 2009; Carr et al., 2004; 
Ellis, Husain, Saetta, & Walker, 2004; Green & Krauss., 
2004a, 2004b; Howes, 2004; McGlone, Howes, & 
Joshi, 2004; Petrack, Marx, & Wright, 1996; Rakhee 
& Milap, 2005; Schmid Sandler, & Katz, 1999; Visser 
& Schug, 2006).  In addition, low-dose ketamine has 
successfully served as an effective adjunct to standard 
opioid therapy, as well as an adjunct to various non-
opiate analgesic agents (Schmid, Sandler, & Katz, 1999).
One of the reasons ketamine has been 
repeatedly studied and scrutinized is its uniqueness 
among all other sedatives, hypnotics, and analgesics 
(primarily opiates, barbiturates, and benzodiazepines). 
The standard definition of conscious procedural sedation 
is dose-dependent alterations in consciousness that result 
in mild to deep sedation, preserving responsiveness to 
verbal or tactile stimuli. Ketamine, in contrast, exerts 
its effect through a functional and electrophysiological 
dissociation or disconnect between the thalamo-
neocortical and limbic areas of the brain (Green & 
Krauss, 2004a, 2004b; Krupitsky & Grinenko, 1997; 
Mistry & Nahata, 2005). Therefore, it does not have a 
characteristic dose-response continuum by progressive 
titration; the dissociation is present or absent with a 
very narrow transition zone (Mistry & Nahata, 2005). 
At doses below a certain threshold, ketamine produces 
analgesia and anxiolysis; however, once the critical dosage 
threshold of roughly 1 – 1.5 mg/kg IM (or 0.5 – 0.75 
mg/kg IV) is reached, the characteristic dissociative state 
abruptly appears (Krauss & Green, 2006). Furthermore, 
dissociation is described as a “trance-like cataleptic 
state” of “sensory isolation” (Mistry & Nahata, 2005), 
meaning little or no responsiveness is present.
Most importantly, unlike other traditional 
sedatives, ketamine usually preserves cardiovascular 
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stability, spontaneous respirations and protective airway 
reflexes, even when exerting its full effect (Green & 
Krauss, 2004a, 2004b; Mistry & Nahata, 2005). 
Because of this, the dissociative state is not consistent 
with the definitions of conscious sedation (Green & 
Krauss, 2004a, 2004b; Krauss & Green, 2000, 2006), 
which has resulted in a separate definition for ketamine 
procedural sedation, namely “dissociative sedation” 
(American College of Emergency Physicians, 2005). 
It should be noted that ketamine is a nonreversible 
agent; once the dissociative state is initiated, it cannot 
be aborted (Alonso-Serra & Wesley, 2003; White et al., 
1982). 
Ketamine performs as a superior fast-acting 
analgesic and anxiolytic in low doses (0.2 – 0.3 mg/kg 
IV, 0.5 – 1 mg/kg IM and intranasal, and 1 – 2 mg/kg 
sublingual and oral), as an effective reliable sedative in 
medium doses (0.5 – 0.75 mg/kg IV, 1.5 – 4 mg/kg IM), 
and a safe short-acting anesthetic in high doses (1 – 4.5 
mg/kg IV and 6.5 – 13 mg/kg IM). 
Ketamine-Induced Emergence Phenomena
Although ketamine is biologically safe in most instances of medical use and has an excellent safety 
profile, it is not without controversy, as it generates 
peculiar psychological side-effects (vivid imagery, 
visual hallucinations, excitement, irrational behavior) 
dubbed “emergence delirium,” it has a high dependence 
potential when abused, and use in a drug-abuse context 
has recently resulted in multiple reports of harm to 
the kidney and bladder (cystitis) in some people (e.g., 
Bokor & Anderson 2014; Meng et al., 2013; Selby et al., 
2008; Tam et al., 2014; Wood, 2013). This has become 
a fairly hot topic in, for example, Hong Kong urology, 
where ketamine abuse is rife, but appears not to have 
been specifically reported by long-term heavy users of 
medically-sourced ketamine such as John Lilly, and 
those who contributed to one of our author’s (Jansen, 
2001) book, Ketamine: Dreams And Realities. However, 
some of the latter did complain of mysterious “K pains” 
in the pelvic region, and it seems increasingly likely 
that these persons may have been susceptible to these 
urological issues as the evidence continues to mount, 
from multiple medical specialists in multiple countries, 
that some long-term heavy users are susceptible to 
urological side-effects. There have also now been animal 
studies pointing to a mechanism (e.g., Gu et al., 2014), 
so this is unlikely to be one of those random panics that 
have characterised the War on Drugs (e.g., scare tactics, 
such as “LSD damages your chromososmes”) that were 
later discredited as propaganda (Dishotsky, Loughman, 
Mogar, & Lipscomb, 1971.)
 Domino was the first clinician who documented 
that 30% of patients had an “emergence delirium” 
after ketamine anesthesia (Domino et al., 1965). 
Subsequently, he asked Parke-Davis to contact Elliot 
Luby, a psychiatrist at the Lafayette Clinic, who had 
previously used phencyclidine (Sernyl) to induce the 
same phenomena in normal volunteers and psychiatric 
patients (Domino, 2010). The Parke-Davis researchers 
were concerned that Luby would conclude that ketamine 
was schizophrenomimetic, which would perhaps result 
in the Parke-Davis executives and lawyers stopping its 
development. It was a reasonable concern, as Luby earlier 
documented that phencyclidine-induced states had 
similarity to “schizophrenic syndrome” (Luby, Cohen, 
Rosenbaum, Gottlieb, & Kelley, 1959). Consequently, 
Parke-Davis insisted that their own psychiatrist observed 
the subjects recovering from ketamine anesthesia. This 
psychiatrist concluded the subjects had an emergence 
reaction quite similar to diethyl ether (Domino, 2010).
 Emergence delirium is not a new phenomenon 
in clinical practice. Eckenhoff and colleagues (1961) 
had reported the signs of “hyperexcitation” in patients 
“emerging” from diethyl ether, phencyclidine, or 
cyclopropane anesthesia. This phenomenon refers to 
a clinical condition in which patients experience a 
variety of “behavioral disturbances,” including crying, 
disorientation, sobbing, and thrashing during early 
emergence from anesthesia (Eckenhoff et al., 1961). 
Emergence delirium (a.k.a. “emergence reaction,” 
“emergence agitation” and “emergence excitation”) 
is defined as the disturbance of a patient’s attention 
to and awareness of the environment accompanied 
by disorientation, hyperactive motor behavior, and 
perceptual alterations immediate postanesthesia (Sikich 
& Lerman, 2004).
 Parke-Davis understandably selected the less 
frightening name of “emergence phenomenon” rather than 
“delirium,” and seems to have underreported the frequency 
of this controversial side-effect. For many years, Parke-
Davis reported on their ketamine (Ketalar) data sheet that 
the frequency of emergence phenomena was only 12%. 
This number was too low, however, and was eventually 
dropped from their later data sheet (Parke-Davis Product 
Information Sheet, 1999-2000). The actual percentage 
reporting emergence phenomena after ketamine anesthesia 
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is close to 40% in many studies (Abajian et al., 1973; 
Hervey & Hustead, 1972; Khorramzadeh & Lofty, 1973; 
Krestow, 1974; O’Neil, Winnie, Zadigian, & Collins, 
1972; Overton, 1975; Sadove, Shulman, & Fevgold, 
1971). One study even reported a 100% incidence range 
of emergence phenomenon (Garfield, Garfield, Stone, 
Hopkins, & Johns, 1972).
 It was quickly discovered that “emergence 
phenomena” may occur independently of anesthesia 
and can be reliably generated by an administration of a 
sub-anesthetic dose of ketamine. Collier reported that, 
at one-sixth to one-tenth of the dose used for general 
anesthesia, ketamine can create psychedelic experiences 
with disconnection from surroundings, perception of 
floating, becoming disembodied as a mind or soul, and 
even dying and going to a different world (Collier, 1972). 
He also noted that loss of reality contact appears more 
pronounced than with other psychedelics.  In addition, 
Collier reported that dissociative experiences often 
seemed so authentic that users were not sure whether 
they had or had not actually become “disembodied.”
 The discovery that ketamine is a powerful 
psychedelic drug did not end its popularity as 
an outstanding anesthetic agent. Instead, use of 
benzodiazepines (the most frequently used are 
midazolam, lorazepam, and diazepam) and increasingly 
propofol have been utilized to control emergence 
problems due to their strong amnestic and dream-
suppressing properties. In addition, the combined use 
of ketamine and benzodiazepines or propofol has the 
advantage of providing increased sedation and anxiolysis 
(Cartwright & Pingel, 1984; Domino et al., 1984; 
Dundee, 1990; Haas & Harper, 1992; Tobin, 1982; Toft 
& Romer, 1987; White et al., 1982; White et al., 1988).
Ketamine as a Psychedelic Drug
The ketamine dissociative experience (emergence phenomena) is, in fact, a non-ordinary state of 
consciousness (NOSC) during which the individual’s 
awareness and perception are dramatically changed 
and radically refocused. This psychedelic experience is 
often induced by intramuscular injections of ketamine 
in doses that are typically used for dissociative sedation 
and lasts from 45 minutes to one hour.  The patient 
completely loses contact with external reality and gets 
involved in a profound psychedelic experience. The 
ketamine-induced non-ordinary states of consciousness 
may include (Collier, 1972; Jansen, 1989a, 1989b, 1997; 
Khorramzadeh & Lofty, 1976; Kolp et al., 2006, 2007; 
Krupitsky et al., 1992; Krupitsky & Grinenko, 1996, 
1997; Krupitsky & Kolp, 2007; Lilly, 1968; Moore & 
Alltounian, 1978; Weil & Rosen, 1983):
• Feelings of leaving one’s body (i.e., out-of-body 
experience)
• Awareness of becoming a non-physical being
• Emotionally intense visions (e.g., of deceased 
relatives, “angels,” “spirits”)
• Encounters with archetypal beings (e.g., Christ, 
Buddha, Krishna)
• Encounters with non-terrestrial beings (e.g., 
“space aliens”)
• Visits to mythological realms of consciousness
• Re-experiencing the birth process
• Vivid dreams and memories of past or future 
incarnations
• Experience of psychological death and rebirth 
of self (i.e., near-death experience)
• Feelings of ego dissolution and loss of identity
• Experience of reliving one’s life
• Deep feelings of peace and joy
• Sense of transcending normal time and space
• Feelings of interconnectedness with all people 
and nature
• Feelings of cosmic unity with the Universe and 
God
• Sense of sacredness
• Profound sense of ineffability of the experience
• Intuitive belief that the experience is a source 
of objective truth about the nature of “absolute 
reality.”
 John Lilly, an American neuroscientist, 
psychiatrist, and “psychonaut” (explorer of his own 
mind, often with the aid of substances), began a series 
of self-experiments with psychedelic substances in the 
early 1960s. Initially, he used LSD, which he sometimes 
self-administered in a sensory isolation flotation tank 
(Lilly, 1972). Circa 1971, Lilly started an exploration of 
the use of ketamine by self-administering various doses 
of ketamine via intramuscular injections, often using an 
isolation tank to enhance its effects (Lilly, 1978).
 Lilly documented a relationship between 
dosage levels and the qualities of ketamine experiences 
that he himself had. He reported that intramuscular 
injections of ketamine at 25 mg did not cause visual 
images, whereas over 30 mg it produced such images 
when eyes are closed. At above 50 mg, visual images 
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became stronger; however, in his case there was no 
dissociation of the mind from the body. At above 75 
mg, visual images significantly increased and feelings of 
detachment of the mind from the body began. At above 
100 mg, visual images became intense even when the 
eyes were open, and feelings of complete dissociation of 
the mind from the body were common. At above 150 mg, 
the mind completely disconnected from the body and 
feelings of total dissolution of ego were common. The 
doses above 300 mg produced unconsciousness (Lilly, 
1978). However, like many long-term ketamine users, 
Lilly developed a notable tolerance to ketamine over 
the years, and thus his own dose-response relationships 
changed (summarized in Jansen, 2001).  Lilly proposed 
utilizing ketamine as a psychotherapeutic agent by using 
ketamine-induced non-ordinary states of consciousness 
for reprogramming the interface of brain-mind, and also 
described ketamine’s antidepressant effects (Lilly, 1972). 
Ketamine-Induced Non-Ordinary 
States of Consciousness
Ketamine induces at least four distinct NOSCs that depend on at least three major factors (as is the case 
with all other classical hallucinogenic substances): the 
dose of ketamine, the physical “setting” of the ketamine 
administration, and the mindset (often just referred to as 
“set”) of the person prior to the ketamine administration 
(see Table 1). These different states of consciousness may be 
partly distinguished by: a) the degree of a dissociation of the 
mind from the body, and b) the degree of ego dissolution. 
   In considering the effects of substances on a 
person, amongst other factors it is necessary to consider 
the dose taken, how it is taken, and the speed at which it is 
taken, the size and gender of the person, other substances 
taken (either before, at the same time or afterwards), the 
tolerance of the individual, and the set and setting. The 
term set includes personality, past experiences, mental 
health, mood, motivations, intelligence, imagination, 
attitudes, what is going on in his or her life, and his or her 
expectations. The term setting refers to the conditions 
of use, including the physical, social, and emotional 
environment, including the other people present. 
 The first state is an empathogenic (or “generating 
a state of empathy” or “heart-opening”) experience.  The 
term “empathogenic” was proposed in the early 1980s 
by Ralph Metzner, and is generated in response to an 
injection of a low sub-psychedelic dose of ketamine, 
Table 1. Ketamine-induced non-ordinary states of consciousness
State   Features    Typical Ketamine Dose Duration
Empathogenic Experience Awareness of body; comfort and relaxation;  Low sub-psychedelic dose similar to  45-60 mins 
   reduced ego defenses; empathy, compassion,  that used for anxiolysis and/or    
   and warmth; love and peace; euphoria; mind is  analgesia (0.25 mg/kg – 0.5 mg/kg IM,
	 	 	 dreamy	with	non-specific	colorful	visual	effects	 or	25	–	50	mg	IM)
Out-of-Body Experience Complete separation from one’s body;   Medium psychedelic dose such as 45-60 mins
(OBE)	 	 	 significantly	diminished	ego	defenses;		 	 that	used	for	mild	conscious
   visits to mythological realms of consciousness;  dissociative sedation (0.75 mg/kg – 
	 	 	 encounters	with	non-terrestial	beings;		 	 1.5	mg/kg	IM,	or	75	mg	–	125	mg	IM)
   emotionally intense visions (e.g., deceased 
	 	 	 relatives,	spirits);	vivid	dreams	of	past	and	future	
   incarnations; re-experiencing the birth process
Near-Death Experience  Departure from one’s body; complete ego  High psychedelic dose such as that 45-60 mins
(NDE)	 	 	 dissolution/loss	of	identity;	experienced	physical	 used	for	moderate	to	severe
	 	 	 (body)	and	psychological	(mind)	death;		 	 conscious	dissociative	sedation
   experience being a single point of consciousness (2.0 mg/kg – 3.0 mg/kg IM, or 
	 	 	 simply	aware	of	itself;	reliving	one’s	life;			 150	–	250	mg	IM)
   aware of how actions have affected others,
   with moral judgment of self
Ego-Dissolving   Ecstatic state of the dissolution of boundaries Rare in low doses (0.25 mg/kg –  45-60 mins
Transcendental	Experience	 between	the	self	and	external	reality;	complete	 0.5	mg/kg	IM,	or	25	–	50	mg	IM),	
(EDT)	 	 	 dissolution	of	one’s	body	and	self	(soul);		 more	common	in	high	psychedelic			
   transcending normal mass/time/space   doses (2.0 mg/kg – 3.0 mg/kg IM, 
	 	 	 continuum;	collective	consciousness;	unity	with	 or	150	–	200	mg	IM)
   Nature/Universe; sacredness
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the type of dose that may be used for anxiolysis and/or 
analgesia (0.25 mg/kg – 0.5 mg/kg IM, or 25 mg – 50 
mg IM). This state lasts from 45-50 minutes to 1-2 hours 
and may be characterized by the following features:
• The awareness of the body remains well-
preserved
• The body feels very comfortable and relaxed
• The ego functioning is well-
maintained;however, the ego defenses are 
significantly lessened
• The person experiences feelings of empathy and 
compassion for themselves
• The mind feels emotional warmth, well-being, 
and joy
• Strong feelings of love and peace are prevailing
• Feelings of euphoria, pleasure and joy are 
common
• Feelings of ecstasy and enhanced sensuality are 
frequent
• The mind is dreamy with frequent non-specific 
colorful visual effects 
• The person may feel they have forgiveness and 
understanding of themselves and for those with 
whom they have important relationships.
It is also entirely possible for these doses to produce 
marked dysphoria and other unpleasant changes in 
mental and physical state. This is far more likely to 
happen if the set and setting are negative.
 The empathogenic NOSC is like the state induced 
by sub-psychedelic doses of classical hallucinogenic 
substances (LSD, psilocybin, DMT, mescaline, etc.), 
or regular doses of classical empathogenic substances 
(MDA, MDMA, 2-CB, etc.). This state can be combined 
with guided imagery or verbalized meditations and may 
sometimes be utilized to resolve long-standing intra-
psychic conflicts, to treat the aftereffects of trauma in 
the victims of physical and sexual abuse or other assault, 
to control the symptoms of post-traumatic stress disorder 
(e.g., in soldiers), or to resolve interpersonal problems in 
spousal and family relationships. Unlike the other three 
NOSC, which are more intense and overpowering, an 
empathogenic experience is more likely to leave the 
patient with an ability to consciously recall this particular 
non-ordinary state of consciousness.
 The second NOSC is an “out-of-body experience” 
(OBE), and may be induced in response to an injection 
of a medium psychedelic dose of ketamine, which is in 
the range used for mild conscious dissociative sedation 
(0.75 mg/kg – 1.5 mg/kg IM, or 75 mg – 125 mg IM). 
This state lasts from 45 minutes to 1 hour and may be 
characterized by the following features:
• Feelings of complete separation from one’s body
• The ego defenses are significantly diminished; 
however, the rudimentary ego structure is still 
preserved and the experiencer is well-aware of 
the self
• Awareness of becoming a non-corporeal being
• Apparent visits to mythological realms of 
consciousness
• Apparent encounters with non-terrestrial 
beings (e.g., “space aliens”)
• Emotionally intense visions (e.g., deceased 
relatives, “angels,” “spirits”)
• Encounters with archetypal beings (e.g., 
Krishna, Buddha, Christ)
• Vivid dreams and memories of past or future 
incarnations
• Re-experiencing the birth process.
This NOSC is similar to the state that can sometimes 
be induced by medium doses of classical hallucinogenic 
substances (LSD, psilocybin, mescaline, etc.), although 
the visions are more realistic, well-defined, and 
frequently get organized into a specific “story.” This type 
of experience can bring to the conscious awareness a 
plethora of unconscious material and may be utilized as 
an adjunct to psychodynamic psychotherapy. This state 
may sometimes be enhanced when combined with calm, 
evocative music (e.g., classical, Trance, or New Age) to 
assist with relaxation and immersion into the experience. 
Unlike an empathogenic experience, OBE leaves the 
person with only a partial ability to consciously recall 
all details of this particular NOSC after the experience, 
partly due to an avalanche of phantasmagoric visions 
and sensory overload, and partly for physical reasons as 
more extensive NMDA receptor blockade interferes with 
memory formation (Collingridge, 1987; Jansen, 1990a, 
1990b).
 The third NOSC is a “near-death experience” 
(NDE), which may be induced by an injection of a high 
psychedelic dose of ketamine, in the range that may 
be used for moderate to severe conscious dissociative 
sedation (2.0 mg/kg – 3.0 mg/kg IM, or 150 – 250 mg 
IM). This state lasts from 45 minutes to 1 hour and is 
characterized by the following features:
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• Feelings of complete departure from one’s body
• Feelings of complete ego dissolution and loss of 
identity
• A strong belief of being physically dead
• Experience of psychological death of the mind 
(the self)
• Feelings of becoming a single point of 
consciousness (the Self, or a soul) that is simply 
aware of itself with no other points of reference
• Sensations of moving through a tunnel
• Experience of reliving one’s entire life
• Becoming aware that one is responsible for 
every thought, word, and action of one’s life 
prior to the NDE
• Awareness of how others were affected by one’s 
thoughts, words, and actions
• Performing the moral judgment of the self 
based on one’s own sense of right and wrong 
holding one accountable for one’s thoughts, 
words, and actions
• Experience of visiting non-physical realities 
(either paradisiacal or hellish realms of 
consciousness) based on one’s own self-
judgment
• Encounters with non-corporeal entities
• Experience of visiting an eternal, featureless 
void (nothingness)
• Experience of psychological rebirth of the ego.
This NOSC is similar to the state that is sometimes 
induced by high doses of classical hallucinogenic 
substances (e.g., LSD, psilocybin, DMT, mescaline), 
although the visions may be more intense, well-
structured, and liable to become organized into a 
form of life review. Some research has found that 
approximately 70% of NDEs are accompanied by 
feelings of calm and peace, while about 30% of NDEs 
are very frightening (Greyson, 1983; Greyson & 
Stevenson, 1980). This NOSC type of experience can 
sometimes bring enhanced insight into one’s deeds and 
misdeeds, and may sometimes be very beneficial as an 
adjunct to existential psychotherapy as well as to so-
called “ego death/rebirth” psychotherapy (Krupitsky & 
Grinenko, 1997; Kungurtsev, 1991). This state may also 
be combined with non-associative, evocative music to 
assist with an immersion into the experience. Similar to 
the OBE, the NDE leaves the patient with only a partial 
ability to consciously recall this particular NOSC on 
the following day, although key features of the overall 
experience may be surprisingly well-remembered 
(i.e., surprising because ketamine’s action at NMDA 
receptors and on neurotransmitters is likely to impede 
short-term memory.)
 Ketamine’s ability to replicate NDEs is 
well-documented (Collier, 1972; Domino, Chodoff, 
& Corssen, 1965; Ghoneim, Hinrichs, Mewaldt, 
& Petersen, 1985; Grinspoon & Bakalar, 1979; 
Kungurtsev, 1991; Lilly, 1968; Rumpf et al., 1969; 
Siegel, 1978, 1980, 1981; Sputz, 1989; Stafford & 
Golightly, 1967; White et al., 1982).  One of our authors 
(Jansen) analyzed similarities between ketamine-
induced transpersonal experiences and NDEs in 
a series of studies, concluding that 150-200 mg of 
ketamine can reproduce all of the features commonly 
associated with NDEs (Jansen, 1989a, 1989b, 1990a, 
1990b, 1991, 1997, 2001). Three of this paper’s authors 
(Jansen, Kolp, & Sylvester) had personal NDEs 
from natural causes, as well as NDE-like ketamine-
induced experiences, and can personally verify the 
striking similarities between both phenomena (e.g., 
a compelling sense of being dead, sensations of 
moving through a tunnel, one’s life review, visits of 
non-physical realities, encounters with non-corporeal 
entities, an experience of the void).
NDEs can be very transformative in some 
people, and can induce positive changes in spiritual 
development and worldview (Ring, 1980, 1984; Ring 
& Valeriano, 1998). Ketamine-induced NDEs appear 
to be equivalent to natural NDEs and may facilitate 
stable recovery by accelerating patients’ psycho-
spiritual growth and broadening their worldviews 
(Kolp et al., 2007, 2009; Krupitsky & Grinenko, 1997; 
Krupitsky & Kolp, 2007). In addition to bringing 
an insight into one’s existential problems, the NDE 
can also generate a spontaneous resolution of the 
patient’s addictive illnesses, psychological problems, 
and personality disorders. These experiences can also 
generate a spontaneous spiritual conversion and a 
dramatic improvement in moral character (Kolp et al., 
2007, 2009; Krupitsky & Grinenko, 1997; Krupitsky 
& Kolp, 2007).
 The fourth type of NOSC is perhaps the 
most fascinating and sometimes the most potentially 
beneficial ketamine-induced experience, as it is an ego-
dissolving transcendental (EDT) experience (an ecstatic 
state of the dissolution of boundaries between the self 
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and external reality) which may be characterized by the 
following features:
• Feelings of complete dissolution of one’s body
• Feelings of complete dissolution not only of ego 
but also the self
• Sense of transcending normal mass/space/time 
continuum
• Feelings of interconnectedness with all 
people (or sense of experiencing collective 
consciousness)
• Feelings of cosmic unity with nature
• Feelings of cosmic unity with the universe
• Feelings of becoming a “Unified Field”
• Feelings of becoming God, frequently 
experienced as an ocean of brilliant white light 
• Deep feelings of love, peace, serenity, joy, and 
bliss
• Profound sense of sacredness of the experience
• Profound sense of ineffability of the experience
• Intuitive belief that the transcendental 
experience is a source of objective truth about 
the nature of absolute reality.
There are some indications that the EDT experience is 
not always dose dependent and may occur even with a 
low dose of ketamine (0.25 mg/kg – 0.5 mg/kg IM, or 
25 – 50 mg IM), although it is more frequent with a 
high psychedelic dose of ketamine (2.0 mg/kg – 3.0 mg/
kg IM, or 150 – 250 mg IM). The EDT experience may 
last from 45 minutes to 1 hour and may be an excellent 
adjunct to transpersonal psychotherapy.
 Similar to the NDE, the EDT experiences 
sometimes generate some resolution of the patient’s 
addictive illnesses, psychological problems, and 
personality disorders, including instances of spontaneous 
healing from chronic psychosomatic illnesses, 
particularly where these are dissociative/conversion in 
type. In addition, there are some anecdotal accounts of 
patients who had a spontaneous remission of some forms 
of serious medical disease (Fenwick & Fenwick, 1995; 
Grey, 1985; Morse & Perry, 1992; Ring & Valeriano, 
1998; Roud, 1990). Like NDEs, EDT experiences have 
the advantages of potentially rapidly accelerating patients’ 
psychospiritual growth, broadening their worldviews, 
and possibly generating a spontaneous spiritual change 
with an improvement in moral character (Kolp et al., 
2007, 2009; Krupitsky & Grinenko, 1997; Krupitsky & 
Kolp, 2007).
Psychedelic Psychotherapy
The acute psychological effects of ketamine can be psychedelic in nature. There are many previous 
studies on the effectiveness of psychedelic psychotherapy 
(Grinspoon & Bakalar, 1979; Grof, 1980; Jansen, 1997, 
2001; Khorramzadeh & Lofty, 1973, 1976; Kolp et al., 
2006, 2007, 2009; Krupitsky & Kolp, 2007; Krupitsky 
et al., 1992, 1997, 2002; Kurland et al., 1971; Leary, 
Metzner, & Alpert, 1964; Roquet, 1974; Strassman, 
1995) suggesting that incorporating a psychedelic 
experience into psychotherapy may have beneficial 
effects in many ways, including: 
• Contributing to the cathartic process
• Stabilizing positive psychological changes
• Enhancing personal growth and self-awareness
• Catalyzing insights into existential problems
• Increasing creative activities
• Broadening spiritual horizons
• Harmonizing relationships with the world and 
other people.
Although the ceremonial and therapeutic uses of 
hallucinogenic drugs have been known worldwide for 
millennia (Furst, 1972; Schultes & Hofmann, 1979), 
scientific research of psychedelic-assisted psychotherapy 
began more recently. Some of the experiments of 
the great British chemist Sir Humphrey Davy, later 
President of the Royal Society, with nitrous oxide at the 
Pneumatic Institution at Bristol, in the late 18th and early 
19th century, hinted at what was possible; unfortunately, 
the opportunity was entirely missed, including the 
opportunity to develop nitrous oxide as what would have 
been the first anesthetic, with Sir Davy later dismissing 
his experiments into the effects of nitrous oxide on the 
mind as frivolous. Consequently, surgical operations 
continued to cause terrible pain for at least another 
100 years. The failure to see the opportunities was 
partly cultural and has been related to the 19th century 
cultural attitude to pain (Holmes, 2008). Cultural 
attitudes, rather than issues genuinely related to science 
and medicine, may currently play an important role in 
greatly restricting the use of psychedelic psychotherapy 
in contemporary society, but there are some signs of a 
thaw.
 The Italian psychoanalyst Baroni (1931) started 
using a mixture of mescaline and Datura stramonium as 
an aid in psychoanalytical psychotherapy in the 1920s, 
and the work of Meduna (1950) with carbon dioxide 
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is also worthy of note. However, psychedelic research 
largely began in the 1950s, after Sandoz Laboratories 
distributed lysergic acid diethylamide (LSD) and 
psilocybin to all researchers interested in hallucinogen-
assisted therapy. Since then, the scientific investigation 
into psychotherapeutic uses of psychedelic drugs has 
been conducted in many countries and resulted in the 
release of dozens of books and more than 1000 peer-
reviewed clinical papers reporting the use of psychedelic 
substances administered to more than 40,000 subjects 
(Dyck, 2005; Grinspoon & Bakalar, 1979; Passie, 1997). 
Numerous clinical research studies of the subjects treated 
with psychedelic compounds, performed from the late 
1950s through the present time, repeatedly demonstrated 
sometimes impressive treatment outcomes (e.g., Grob, 
1998, 2002; Grof, 1980; Grinspoon & Bakalar, 1979; 
Kolp et al., 2006, 2007, 2009; Krupitsky & Kolp, 2007; 
Pahnke, 1968, 1969; Pahnke, Kurland, Goodman, & 
Richards, 1969; Pahnke, Kurland, Unger, Savage, & 
Grof, 1970; Pahnke, Kurland, Unger, Savage, Wolf, & 
Goodman, 1970; Pahnke, McCabe, Olsson, Unger, & 
Kurland, 1969; Richards, 1979/1980; Richards, Grof, 
Goodman, & Kurland, 1972; Richards et al., 1979; 
Richards, Rhead, DiLeo, Yensen, & Kurland, 1977; 
Walsh & Grob, 2005; Watts, 1973; Yensen & Dryer, 
1993/1994). 
 Hallucinogen-assisted psychotherapy evolved into 
three major methodologies: hypnodelic psychotherapy, 
 psycholytic (“mind-loosening”) psychotherapy, and psyche-
delic (“mind-manifesting”)  psychotherapy. Hypnodelic 
psychotherapy has its goal as being to maximize the 
power of hypnotic suggestion by combining it with the 
low (sub-psychedelic) doses of hallucinogenic substances 
in order to lower ego defenses without actually creating 
a visionary experience (Grof, 1980). Hypnodelic 
psychotherapy goes back to the nineteenth century, when 
ether, nitrous oxide, and chloroform were used to induce 
and deepen hypnotic states (e.g., Schrenck-Notzing, 
1891). Later on, a procedure called “narcoanalysis” was 
developed to use an amphetamine/barbiturate-induced 
state of excitation/sedation to recall repressed conflicts 
(Horsley, 1943). Its use in the treatment of “traumatic 
combat neuroses” (one of the former names for post-
traumatic stress disorder) attained some importance 
(Grinker & Spiegel, 1945).
 Psycholytic therapy (a.k.a “psycholysis”) involves 
the use of medium doses of psychedelic drugs that create 
a powerful mind-altering experience without dissolution 
of ego functioning (Eisner, 1997; Eisner & Cohen, 1958; 
Leuner, 1967). This technique was regularly practiced 
in numerous European treatment centers during the 
1950s and 1960s. In 1954 Sandison and Spencer 
reported “abreactive memory actualizations” leading to 
a remarkable progress of “neurotic” patients treated with 
LSD (Sandison & Spencer, 1954). Around the same 
time Leuner (1959) developed a day-dream technique 
in psychotherapy that became established through the 
present time as “guided affective imagery” (Leuner, 
1977, 1984). He documented that treatment with low 
doses of hallucinogens predictably generated regression 
and catharsis experiences in his psychotherapy patients 
(Leuner, 1959, 1971, 1977, 1984). 
 The earlier investigators reported that 
psycholytic psychotherapy (or psycholysis) presented 
to psychotherapists unique opportunities to overcome 
rigid defense mechanisms in treatment-resistant patients 
(Arendsen, 1963; Leuner, 1971; Mascher, 1967). Other 
reported advantages of psycholysis, in addition to the 
amplification of psychotherapeutic process, were its 
capacity to increase the effectiveness of treatment and 
to shorten the length of psychotherapy to half of the 
typical time (Arendsen-Hein, 1963; Leuner, 1971, 1977, 
1984; Mascher, 1967).
 Psychedelic therapy involves the use of higher 
doses of hallucinogenic drugs, with the aim of inducing 
ego-dissolving transpersonal (e.g., transcendental, 
mystical, spiritual) peak experiences (Grinspoon 
& Bakalar, 1979; Grob, 1998, 2002; Grof, 1978, 
1980, 1986; Grof & Halifax, 1976; Grof, Goodman, 
Richards, & Kurland, 1973; Pahnke, 1968; Pahnke 
et al., 1969, 1970; Richards et al., 1972, 1977, 1979; 
Walsh & Grob, 2005; Watts, 1973; Yensen & Dryer, 
1993/1994).  This method was initially developed by 
Hoffer and Osmond in the United States (Hoffer, 
1967). In 1950, they observed that many alcoholic 
patients developed a spontaneous remission after the 
frightening experiences of a delirium tremens (Hoffer, 
1967). Subsequently, they resolved to induce a facsimile 
of delirium tremens with high doses of LSD, in order 
to generate abstinence in alcoholic patients. To their 
surprise, those patients who had positive experiences, 
such as religious, spiritual, or mystical experiences, 
had even longer lasting therapeutic effects (Hoffer, 
1967). Following their original experiments, Osmond 
and Hoffer developed the technique of psychedelic 
psychotherapy based on the induction of mystical 
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experiences. They used a quasi-religious preparation, 
high doses of LSD, specific surroundings, and evocative 
music to attempt to induce a transformative mystical 
state of consciousness (Hoffer, 1967). 
 Pahnke (1962) conducted a double-blind 
experiment and scientifically documented that the 
induction of mystical experiences (“Unio mystica”) can 
generate rapid acceleration of psychospiritual growth. 
His work was further replicated by Leary, Litwin, and 
Metzner (1963) who came to the same conclusion. 
 The reports based on ethnographic observations 
of the ritual administration of certain hallucinogenic 
plants are also relevant. La Barre (1989) and Andritzky 
(1989) documented dramatic positive personality 
changes in individuals with alcoholism who participated 
in indigenous shamanic ceremonies (Peyote cult and 
Brazilian Ayahuasca religion). 
 During the 1960s and 1970s, the psychedelic 
technique was extensively studied and further optimized 
at the NIMH Psychiatric Research Center and Spring 
Grove Hospital (Grof, 1975, 1978; Pahnke et al., 1970; 
Richards et al., 1977; Yensen & Dryer, 1993/1994). 
Both hypnodelic and psycholytic psychotherapies 
were usually conducted repeatedly at intervals of 1-4 
weeks, between 10 and 50 psychotherapeutic sessions, 
in combination with hypnotic, psychoanalytical, or 
psychodynamic psychotherapy (Eisner, 1997; Eisner & 
Cohen, 1958; Grof, 2001; Leuner, 1967). Psychedelic 
psychotherapy generally included one to three sessions 
with a psychedelic agent, greatly depended on set and 
setting, and was generally administered as a part of 
humanistic, existential, or transpersonal psychotherapy 
(Grinspoon & Bakalar, 1979; Grob, 1998, 2002; Grof, 
1978, 1980, 1986; Grof & Halifax, 1976; Grof et al., 
1973; Kolp et al., 2006, 2007, 2009; Krupitsky & Kolp, 
2007; Pahnke, 1968, 1969, 1970; Richards et al., 1972, 
1977, 1979; Walsh & Grob, 2005; Watts, 1973; Yensen 
& Dryer, 1993/1994). 
 Hallucinogen-assisted psychotherapy has 
been used for the treatment of people with a variety of 
psychological problems, including alcoholism and other 
addictive illnesses, anxiety and mood disorders, autism, 
psychosomatic diseases, criminal recidivism, and end-of-
life issues, to name a few. The previous studies asserted 
that the most powerful results from treatment were 
induced by transpersonal (e.g., transcendental, mystical, 
spiritual, or religious) peak experiences (Pahnke, 1968, 
1969; Pahnke, Kurland, Goodman, & Richards, 1969; 
Pahnke, McCabe, Olsson, Unger, & Kurland, 1969; 
Pahnke, Kurland, Unger, Savage, & Grof, 1970; Pahnke 
et al., 1970). This mystical peak experience (an ego-
dissolving non-ordinary state of consciousness) induced 
by psychedelic substances can be in turn used to accelerate 
and enrich the course of psychotherapy. Depending on 
the therapist’s school of thought, the ego-dissolving 
transcendental experience can be used as an adjunct to 
behavioral/cognitive, psychoanalytical/psychodynamic, 
humanistic/existential, or transpersonal psychotherapy. 
Each school of psychotherapy has its advantages and 
shortcomings. However, it seems that psychedelic-
induced non-ordinary states of consciousness may be 
successfully used as an adjunct for several major schools 
of psychotherapy. It is thus understandable that, since 
the early 1970s through to the present time, a number 
of international psychiatric investigators have utilized 
ketamine-induced non-ordinary states of consciousness 
for psychotherapeutic treatment of various psychological 
problems, mental diseases, chemical dependencies, 
psychosomatic illnesses and personality disorders. 
History of 
Ketamine Psychedelic Psychotherapy 
Roquet was the first clinician to publish results from using ketamine for psychedelic psychotherapy, 
which occurred in Mexico (Roquet, 1975; Roquet & 
Favreau, 1981; Roquet, Favreau, Ocana, & Velasco, 
1971). He combined traditional psychoanalytical 
techniques with the shamanic healing practices of 
indigenous Mexican Indian ceremonies and created a 
new approach to psychedelic psychotherapy that he called 
“psychosynthesis” (not the psychosynthesis developed 
by Robertos Assagioli, 1965). Roquet utilized ketamine 
1.5 mg/kg (or approximately 125 mg IM) and treated 
primarily neurotic patients, although he described some 
success with character disorders and selected psychotic 
patients (Roquet, 1975; Roquet & Favreau, 1981; 
Roquet et al., 1971; Yensen, 1973, 1985). His therapeutic 
regimen also incorporated other psychedelic substances, 
such as LSD, mescaline, and psilocybin. Roquet used 
ketamine (and other psychedelic substances) in a group 
setting between 1969 and 1974 and applied his technique 
of psychosynthesis to approximately 150 patients 
(Yensen, 1985). He reported positive outcomes in 85% 
of his patients (Roquet, 1975; Roquet & Favreau, 1981; 
Yensen, 1985).
 Roquet described four levels of possible 
experiences with ketamine (as well as with all other 
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psychedelic compounds he utilized). The first and 
most superficial level is a level of minor perceptual 
distortions. The second level is a level of wish 
fulfillment and fantasy (as the patient merely runs 
from problems with pleasant fantasies). Although 
patients can experience certain mystical states on this 
level, the experience usually does not yield true insight 
and results in only minimum reorganization of the 
personality. The third level is the level of existential 
anxiety and is often characterized by experiences of 
psychological death and rebirth. This level is frequently 
accompanied by the feeling of intense abreaction 
with catharsis afterward. The fourth level is the most 
intense, when the personality disappears completely, 
all previous points of reference are lost, and profound 
reorganization occurs. At this level, true life-altering 
experiences of a mystical nature can take place. Roquet 
regarded this level as essential to successful therapy 
and aimed to synthesize a healthy personality through 
the integrative qualities of this experience (Roquet, 
1975; Roquet & Favreau, 1981; Yensen, 1973).
In Argentina, Fontana (1974) employed ketamine 
as an adjunct to psychotherapy for depression to facilitate 
regression to prenatal levels combining disintegration 
and death followed by progression to rebirth. He reported 
that ketamine allows therapists to introduce themselves 
into, and to correct, primitive experience through the 
relationship. Fontana emphasized the advantages of 
ketamine as making it possible to reach deep levels 
of regressions that had not been observed previously. 
However, we could not find the specific dose of ketamine 
he utilized, the type of psychotherapy he applied to his 
clients, or the specific number of the patients he treated 
with ketamine psychedelic psychotherapy.
 In Iran, Khorramzadeh and Lofty (1973) 
administered ketamine as an “abreactive agent” to patients 
with various psychiatric illnesses (anxiety, depression, 
phobias, obsessive-compulsive neurosis, conversion 
 reaction, hypochondriasis, and hysteria) and psychosomatic 
disorders (tension headaches and ulcerative colitis). Subjects 
were chosen from the inpatient population of a psychiatric 
unit of a university hospital in southern Iran. A total of 
100 patients (61 males and 39 females) were investigated, 
ranging in age from 16 to 66. Patients with organic brain 
syndrome and psychoses were excluded.  
 Ketamine was administered intravenously in 3 
dose ranges in Khorramzadeh and Lofty’s (1973) work. 
The first group (25 patients) received 0.2 – 0.3 mg/kg 
body weight. Of the 25 subjects in this group, only 
one was reported as having a minimal response and 24 
showed no response. These 24 were then given a higher 
dose of ketamine (0.4 – 0.6 mg/kg body weight) along 
with 72 others. A total of 95 demonstrated the abreactive 
response consisting of excitement, emotional discharge, 
verbalization of conflict, and emergence phenomena. 
Of the latter, all had facilitation of their psychotherapy 
and symptom relief. Group 3 included only one failure 
from the group 2 as well as 3 new patients. They received 
0.7 – 1.0 mg ketamine/kg of body weight. According to 
the authors, all of these patients showed the abreactive 
response and had facilitation of their psychotherapy with 
symptom relief. In total, 74 subjects had intense visionary 
experiences; out of those, 51 patients recalled vividly 
painful childhood events regarding the key figures in 
that period. The complications were described as very 
minimal and included apprehension (2 subjects), nausea 
(3 subjects), and vomiting (2 subjects), which were treated 
with perphenazine (5 mg IM) with positive response.
 Khorramzadeh and Lofty’s (1973) subjects 
were seen 6 months after the injection. Only 9 patients 
were not doing well at this time, while ninety-one of 
the patients were doing quite well. After one year, 88 
patients were still being observed and all except two 
were reported to be doing well (one had ulcerative colitis 
and the other tension headaches). They both requested 
another injection which was given and led to relief of 
symptoms for an unspecified period of time. They 
postulated that ketamine activated unconscious and 
repressed memories, while it could temporarily transport 
the patient back into childhood, reviving traumatic 
events with intense emotional reaction. They also 
concluded that ketamine’s cathartic effect was related to 
its mind-expanding qualities and recommended the use 
of this chemical as an abreactive agent.
 Khorramzadeh and Lofty (1976) later 
conducted another study to determine the types 
of ketamine-induced emergence phenomena and 
to discover any possible correlation between this 
phenomena and the type of personality involved. They 
used Eysenck’s Personality Inventory (EPI) to evaluate 
the three dimensions of personality (Extraversion or E, 
Neuroticism or N, and Psychoticism or P) in patients 
who undertook ketamine anesthesia during surgery. A 
total of 606 patients were given a Persian adapta tion of 
EPI the night before Ketamine anesthesia for operation. 
The maximum score accepted as normal for E and N 
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was 11, and for P was 5. When E fell below 5, it was 
considered an indication of Introversion. Out of 606 
patients, 394, or 65%, showed no reaction. All of them 
had normal scores. The re maining 212 patients, or 35%, 
fell into the following seven groups, according to their 
various scores:
• Group E. Sixty-five patients (l0.7%) scored high in 
E (over 14). They experi enced pleasant dreams, and 
some of them even felt they were in heaven among 
angels. Later questioning showed that they were 
all devoted Moslems. All of them expressed their 
willingness to undergo the ex perience again.
• Group N. Seventy patients (11.5%) had high 
scores in N (over 14). They all felt dizzy and 
related that to an experience of falls or rapid 
circular movements. They were indifferent to 
future use of the agent.
• Group P. Only 15 patients (2.4%) had high 
scores in P. They all reported body image 
distortions, loss of control over their limbs, and 
a sensation of a part of their body floating. In 
some the reaction was such that it had to be 
ended with per phenezine 5 mg IM. All refused 
to go through the experience again.
• Group NP. Fourteen patients (2.3%) scored 
high both for N and P. They had the combined 
experiences of groups N and P, making them 
feel terrified and most apprehensive. They were 
adamantly against future use of ketamine.
• Group PE. Ten patients (1.6%) scored high both 
in P and E. They screamed or laughed and had 
increased motor activity and some used foul 
language, while regaining consciousness. They 
all stated that they had a good time and the 
screaming was because of losing the pleasant 
feeling. They were willing to undergo the 
experience again. 
• Group NE. Eighteen patients (2.9%) had high 
scores in N and E, and although they had the 
feeling of falling or circling, it was not at all 
unpleasant. One male patient stated that it was 
like a funny orgasm without ejaculation. They 
did not mind the future use of ketamine.
• Group Low E. Twenty patients (3.3%) scored 
5 or lower in E. They cried and used profanity 
mostly directed at their close friends and 
relatives. After regaining consciousness, 10 
of them had amnesia but the rest stated that 
they knew they were using profanity but could 
not control it. None wished to go through the 
experience again.
 Khorramzadeh and Lofty (1976) reported that 
the EPI was found to be reliable in predicting the type of 
emergence phenomena. The reported results apparently 
showed that the majority of the patients (65%) did not 
experience emergence phenomena at all (those with 
normal scores). Of the remaining 35%, the majority had 
either pleasant (those with high scores in E, EP, and NE) 
or indifferent (those with high score in N) experiences. 
Only 8% had unpleasant experiences (those with high 
P and NP, and low E). This study supported that, in 
emergency situations requiring keta mine anesthesia, 
the drug may be administered without undue concern 
regarding the emergence phenomena, since only a small 
minority of patients had very unpleasant side effects. The 
study also documented that, in non-emergency situations, 
a simple questionnaire may help the anesthesiologist to 
select suitable candi dates for ketamine induction.
 Psychiatrist Stanislav Grof (1980) developed the 
most comprehensive theory of psychedelic psychotherapy 
from the transpersonal perspective. He wrote that 
psychedelics facilitate therapeutic experiences of symbolic 
death and rebirth of the ego, allowing clients to work 
through deep traumatic fixations in their unconscious. 
Grof designed a specific psychedelic psychotherapeutic 
approach, which he applied successfully with more than 
750 patients. Although Grof primarily used LSD in 
his work, he acknowledged that ketamine holds great 
promise due to its affinity with dynamic systems. He 
reported that the psychoactive effect of ketamine is so 
powerful that it can catapult patients beyond impasses 
from previous LSD sessions to reach higher levels of 
integration (Grof, 1980).
 Last in this regard, we want to mention the 
interesting recent work on DMT and spirituality, in the 
United States by psychiatrist Rick Strassman (2000, 
2014).  We see this as very complementary to our interest 
in ketamine.
Present Research on 
Ketamine Psychedelic Psychotherapy
In Russia, one of us (Evgeny Krupitsky) conducted the most comprehensive, rigorous scientific clinical 
research on ketamine psychedelic psychotherapy to date 
(Krupitsky & Grinenko, 1997; Krupitsky & Kolp, 2007; 
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Krupitsky et al., 1990, 1992, 1999, 2002, 2007). He began 
using ketamine as an agent for psychedelic psychotherapy 
in 1985 in the former Soviet Union. His early exploration 
of the use of ketamine as a psychotherapeutic agent 
employed a behavioral psychotherapy, specifically an 
aversive conditioning model for the treatment of alcohol 
dependence that was customary in Russia before the 
fall of the U.S.S.R. Krupitsky et al. (1992) combined 
traditional behavioristic methods of aversive therapy 
oriented towards creating negative associations between 
the use of alcohol and undesirable physical effects 
with earlier applications of psychedelic psychotherapy 
for treatment of alcoholism that sought to change an 
individual’s attitude towards the use of alcohol but 
failed to imprint negative associations around the use 
of alcohol (Smith, 1964; Smith & Seymour, 1985). He 
created the affective contra-attribution (ACA) method 
that combined both of these approaches.
 Initially, Krupitsky induced an aversive 
psychedelic experience by combining ketamine with 
bemegride (an analeptic agent with strong anxiogenic 
properties) in order to generate the frightening 
emotive experiences and produce strong negative 
emotions towards alcohol in the context of a terrifying 
hallucinatory experience. This forms the basis of the 
ACA method. These negative experiences are connected 
with the use of alcohol and with the alcoholic’s life style. 
Later on, Krupitsky learned that those subjects who 
instead had an ecstatic transpersonal experience had 
equally remarkable, if not greater, beneficial outcomes 
and his work gradually shifted from a behavioral model 
to an existential and eventually transpersonal paradigm 
(Krupitsky & Grinenko, 1997). 
 Krupitsky initially used ketamine as an 
alternative treatment for alcoholism only. His original 
ketamine study demonstrated that KPP is highly 
effective in the treatment of alcohol dependence. Of 111 
patients who received KPP in the first study, 69.8% were 
sober one year later, while only 24% in the control group 
remained abstinent during the one-year follow-up period 
(Krupitsky et al., 1992). 
 Krupitsky summarized his findings and 
documented that his patients became less anxious and 
depressed, more responsible and emotionally mature, 
with increased ego strength and positive changes in self-
concept. His studies also showed that KPP brings about 
profound positive changes in life values and purposes, in 
attitudes to the different aspects of life and death, and 
rapidly accelerates psychospiritual development. Patients 
began to see other purposes, other values, other meaning 
and pleasures in their lives, grew more self-confident and 
balanced, more emotionally open and self-sufficient, 
and more responsible for their lives and the lives of their 
loved ones (Krupitsky & Grinenko, 1997). 
 Krupitsky and his team (1999) also examined 
the effectiveness of KPP for the treatment of heroin 
dependence. The team designed a double-blind 
randomized clinical trial comparing the relative 
effectiveness of a high psychedelic dose of ketamine (2.0 
mg/kg IM) to a low non-hallucinogenic dose of ketamine 
(0.2 mg/kg IM) for the psychotherapeutic treatment of 
heroin addiction. The preliminary 6-month follow up 
demonstrated that a hallucinogenic (psychedelic) dose of 
ketamine was more effective than a non-hallucinogenic 
(sub-psychedelic) dose. Two-year follow-up data 
confirmed that the rate of abstinence in the high-dose 
ketamine group was significantly higher than that in the 
low-dose control group, while the corresponding rate of 
relapse was lower (Krupitsky et al., 2002). 
 This comprehensive study with heroin addicts, 
the first double-blind clinical trial of KPP conducted 
entirely within the evidence-based medical paradigm, 
clearly established that KPP significantly reduced the 
craving for heroin, considerably decreased the levels of 
anxiety and depression, markedly increased the level of 
spiritual development, and, to a great extent, enhanced 
understanding of the meaning and purpose of life. 
Interestingly, many of the measured change variables 
did not differ significantly between high and low dose 
groups. This suggests that the psychotherapy common 
to both groups played an important role in the observed 
effects. This could also be the effect of set and setting 
combined with a relatively low dose of ketamine. In 
addition, the study demonstrated that KPP produced 
few or no significant adverse reactions, and no subject 
participating in the study became addicted to ketamine 
(Krupitsky et al., 1999, 2002).
 Krupitsky’s most recent work employed single 
versus repeated sessions of ketamine-assisted psycho-
therapy in subjects with treatment-resistant heroin 
dependence who do not respond well to the initial 
treatment with KPP (Krupitsky et al., 2007). Fifty-nine 
detoxified inpatients with heroin dependence received 
one KPP session prior to their discharge from an 
addiction treatment hospital, and were then randomized 
into two treatment groups. Participants in the first group 
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received two addiction counseling sessions followed by 
two KPP sessions, with sessions scheduled on a monthly 
interval (multiple KPP group). Participants in the second 
group received two addiction counseling sessions on a 
monthly interval, but no additional ketamine therapy 
sessions (single KPP group). At one-year follow-up, 
survival analysis demonstrated a significantly higher rate 
of abstinence in the multiple KPP group. Thirteen out of 
26 subjects (50%) in the multiple KPP group remained 
abstinent, compared to 6 out of 27 subjects (22%) in the 
single KPP group (p<0.05). Once again, no differences 
between groups were found in anxiety, depression, the 
severity of craving for heroin, or their understanding 
of the meaning of their lives. The data from this study 
provide some evidence that treatment-resistant patients 
who did not experience a mystical state of consciousness 
during the initial ketamine session may benefit from a 
second or even a third ketamine session. It appears that 
two or three repeated KPP sessions may work better and 
provide a higher rate of abstinence in heroin addicts than 
one KPP session, suggesting that increasing the number 
of KPP sessions might increase the efficacy of treatment. 
 Krupitsky’s comprehensive clinical research of 
ketamine psychedelic psychotherapy has clearly documented 
that KPP is a safe and sometimes very effective treatment 
for alcoholism and opioid dependencies. It also proved to 
be efficacious in the treatment of stimulant dependence, 
as well as a very effective modality for the treatment of 
comorbid psychiatric conditions, such as posttraumatic 
stress disorder, neurotic depression, anxiety disorders, and 
avoidant personality disorders. In addition, his scientific 
work demonstrated that KPP might be effective for the 
treatment of phobic neurosis, obsessive-compulsive neurosis, 
and histrionic personality disorder (Krupitsky & Grinenko, 
1997; Krupitsky & Kolp, 2007; Krupitsky et al., 2002). 
 Many of Krupitsky’s patients developed a more 
spiritual approach to life through their transpersonal 
experiences. These encouraging clinical results occurred 
because of positive changes in the life values and purposes, 
relationships, and worldviews of these patients. They 
showed a transformation of emotional attitudes, a decrease 
in the level of inner discord, internal tension, discomfort, 
and emotional isolation; improved self-assessment; and 
a tendency to overcome the passive aspects of their 
personalities. These significant changes, along with a 
positive transformation of the patients’ system of life 
values and meaning, as well as changes in their worldview, 
created a positive attitude toward a sober life and supported 
patients’ ongoing stable sobriety (Krupitsky & Grinenko, 
1997; Krupitsky & Kolp, 2007).
 Unfortunately, changes in the regulations 
governing ketamine research in Russia brought Krupitsky’s 
research efforts to a halt. When Krupitsky began 
working with ketamine psychedelic psychotherapy in 
1985, psychedelics were not widely known in Russia and 
ketamine was a Schedule III drug in that country. After the 
collapse of the U.S.S.R., all drugs, including psychedelics, 
became much more available in Russia, ketamine included. 
Subsequently, ketamine abuse among Russian youth rapidly 
escalated from the late 1990s. The Russian government 
thus moved ketamine from Schedule III into Schedule II 
in 2002. Ketamine remains available only for anesthesia 
and conscious sedation at the present time in Russia. It 
became unavailable for the treatment of addictive disorders 
and psychiatric illnesses, and Krupitsky had to abandon his 
innovative work with KPP. 
Technique of 
Ketamine Psychedelic Psychotherapy
Krupitsky has developed a specific and comprehensive course of KPP that comprises three main stages: 
preparation, administration, and integration (Krupitsky 
& Grinenko, 1997; Krupitsky & Kolp, 2007; Krupitsky 
et al., 1990, 1992, 1999, 2002, 2007). In the preparation 
stage, preliminary psychotherapy is carried out with 
patients, who are told that the psychedelic session may 
induce important insights concerning their personal 
problems, their system of values, their notions of self 
and the world around them, and the meaning of their 
lives. Patients are educated that all of these insights may 
lead to positive changes in their personalities, which will 
be important for healing their underlying problems and 
shifting to a sober lifestyle. At least five to ten hours of 
psychotherapy are provided before the ketamine session 
in order to establish the psychospiritual goal for the 
transpersonal experience and prepare the subject for the 
session. The therapist pays close attention to issues such 
as the patient’s personal motives for treatment, goals for 
a sober life, and ideas concerning the cause of the disease 
and its consequences. The patient and therapist together 
form an individually tailored “psychotherapeutic myth” 
during this dialogue that creates an atmosphere of 
confidence and mutual understanding during the first 
stage of KPP. This then becomes the most important 
therapeutic factor responsible for the psychological 
content of the second stage of KPP (Krupitsky & 
Grinenko, 1997; Krupitsky & Kolp, 2007). 
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 The second stage of this approach to KPP is 
the induction of the transpersonal experience through 
the administration of ketamine. Breakfast is omitted 
on the morning of ketamine administration, and all 
participants refrain from food and drink for at least eight 
hours prior to this experience. Patients are told that they 
will enter some unusual states of consciousness and are 
instructed to surrender fully to the experience. After the 
patient lies down in a comfortable supine position with 
eyeshades, ketamine is injected intramuscularly, in doses 
from 2.0 mg/kg to 2.5 mg/kg. The intramuscular route 
is preferred because the onset is more gradual and the 
psychedelic experience lasts longer. With an intravenous 
psychedelic dose (from 0.7 mg/kg to 1.0 mg/kg), the 
effect lasts only about 15 to 20 minutes, but with an 
intramuscular injection, it lasts from 45 minutes to an 
hour (Krupitsky & Grinenko, 1997; Krupitsky & Kolp, 
2007). 
 With a background of specially chosen music, 
generally free-floating non-associative classical or New Age, 
the patient typically has a powerful non-ordinary state of 
consciousness, frequently resembling a mystical experience. 
After 45 minutes to an hour, the patient slowly comes 
back from the experience. During the recovery period, 
which takes from one to two hours, the patient begins to 
feel ordinary reality returning. At this point in the session, 
the patient usually begins to describe the experience and 
some discussion and interpretation is begun with the 
psychotherapist. After the session, the patient goes to rest. 
The patient is asked to write down a detailed self-report 
of the transpersonal ketamine experience that evening 
(Krupitsky & Grinenko, 1997; Krupitsky & Kolp, 2007).
 The third stage is the integration of the 
ketamine-induced experience, which is carried out after 
the ketamine session. It is generally done in a group 
psychotherapy format, because the dynamic of the shared 
group experience appears more powerful and therapeutic 
than individual therapy alone. From three to five hours 
of psychotherapy are provided after the ketamine session 
to help subjects interpret and integrate their experiences 
during the session into everyday life. With the aid of 
the psychotherapist during the integration phase of 
treatment, the patients discuss and interpret the personal 
significance of the symbolic content of their ketamine-
induced non-ordinary state of consciousness. This 
discussion is directed toward helping the patients make 
a correlation between their psychedelic experience and 
their intra- and interpersonal problems. The therapist 
assists the patients in the psychological integration of 
the spiritual transformation that can result from the 
direct transpersonal experience. This uniquely profound 
and powerful experience often helps patients to generate 
fresh insights that enable them to integrate new, often 
unexpected meanings, values, and attitudes about 
the self and the world (Krupitsky & Grinenko, 1997; 
Krupitsky & Kolp, 2007). 
 It should be explicitly pointed out that a 
ketamine-induced psychedelic experience may have only 
marginal and transitory beneficial effects in and of itself, 
no beneficial effects at all, or may be harmful when 
ketamine is used in uncontrolled settings recreationally. 
It can sometimes lead to significant medical problems 
and addiction (Jansen, 2000, 2001; Jansen & Darracot-
Canckovic 2001; Ricuarte, 2005). The therapeutic 
relationship, as well as set and setting, are paramount to 
the effectiveness of ketamine psychedelic psychotherapy. 
 In order for the KPP sessions to cause positive 
transformative experiences, it is of central importance 
to carefully prepare patients for the KPP session, to 
attentively supervise them during the session, and 
to provide extensive psychotherapy after the session 
to facilitate the integration of the ketamine-induced 
transpersonal experience and to help patients personally 
accept insights gained during the KPP session (Krupitsky 
& Grinenko, 1997; Krupitsky & Kolp, 2007).
Present Use of 
Ketamine Psychedelic Psychotherapy
One of us, Dr. Eli Kolp is a bi-cultural psychiatrist and was originally trained in the former U.S.S.R. as 
a public psychiatrist. After Kolp requested that the Soviet 
authorities allow him to emigrate from the U.S.S.R., he 
was instead sent to work as an addiction specialist in 
the Moscow Alcohol and Drug Abuse Clinic #1, where 
Kolp learned how difficult the treatment of alcoholism 
in Russia could be. Even with the most intensive long-
term treatment, which included multiple sessions of an 
unpleasant aversive conditioning, more than 75% of 
Russian alcoholics relapsed on alcohol within one year 
after completion of treatment. 
 After Kolp immigrated to the United States in 
1981, he successfully re-trained as a private psychiatrist 
and began practicing general adult and geriatric 
psychiatry. Circa 1990, Kolp returned to the treatment 
of addictive illnesses, both in private and public sectors, 
where he directed various outpatient, residential, 
and inpatient programs specializing in the treatment 
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of alcohol, drug, and/or food addiction. He quickly 
learned that efforts to treat alcoholism in the American 
population are costly and have a low rate of recovery, as 
they do in Russia.
 A previous meta-analysis of outcomes of treatment 
for alcoholism (Nathan, 1986) showed that different 
treatment methods did not appear to be associated 
with significantly different long-term outcomes. It was 
reported that treatment factors, including theoretical 
orientation, content, locus, and intensity of treatment 
revealed little or no difference in treatment outcome, 
despite great differences in costs. Although abstinence 
rates one year after treatment may reach 40% to 50% for 
persons with good treatment prospects (well-motivated, 
employed, sub-chronic alcoholics with a large network 
of support and substantial personal resources treated at 
private treatment facilities), typical abstinence rates for 
poorly motivated, unemployed, chronic alcoholics with 
a limited network of support and few personal resources 
seen at public treatment facilities were 25% or less. Rates 
of abstinence at and beyond the two-year mark are often 
less than 50% of the rates of abstinence at the one-year 
mark. 
 In the United States, Kolp, inspired by Krupitsky, 
thus began working towards utilizing ketamine 
psychedelic psychotherapy in 1994. His approach was 
explicitly meant to replicate Krupitsky’s pioneering work 
and to extend it into another cultural context, the United 
States. With Krupitsky’s guidance (while Krupitsky was 
working for one year with Krystal as a visiting scientist 
in the Department of Psychiatry at Yale University), 
Kolp designed a research protocol, entitled The Ketamine-
Assisted Therapy of Alcoholism. The protocol was first 
approved by the Safety Committee of the James A. 
Haley Veterans Hospital in Tampa, Florida, and then 
by the Research and Development Committee of the 
Department of Veterans Affairs. It was further approved by 
the Research Committee of the Department of Psychiatry 
at the University of South Florida College of Medicine 
and the Institutional Review Board of the University of 
South Florida Health Science Center. Finally, by the end 
of 1996, the protocol was approved by the FDA, which 
issued to Kolp an Investigational New Drug permit. 
Unfortunately, the implementation of the protocol never 
materialized due to a lack of the institutional support and 
an absence of research funds. The Department of Veterans 
Affairs did not allow Kolp to use its facility and resources 
for this purpose, apparently because of the controversial 
nature of psychedelic psychotherapy at that point in time, 
which was somewhat prior to the recent “thaw” which has 
allowed some human work to be done with drugs such as 
psilocybin and MDMA (e.g., Friedman, 2006; Griffiths, 
Richards, Johnson, McCann, & Jesse, 2008; Griffiths, 
Richards, McCann, & Jesse, 2006).
 Kolp was also unable to obtain funding for the 
study from multiple sources. It thus became necessary 
to abandon the planned, formal research study. Instead, 
Kolp employed ketamine psychedelic psychotherapy 
(KPP) in his private psychiatric practice. During the 
first several years (1994-1999), Kolp administered (KPP) 
to more than 70 patients. The patients were males and 
females, 21-64 years old, who identified alcohol as their 
drug of choice and satisfied the diagnostic criteria for 
alcohol dependence. Kolp followed all patients treated 
with KPP for as long as they continued the aftercare 
treatment, and he had individual and group sessions 
with them on a regular basis, from once a month to once 
every 3 months. In addition to being diagnosed with 
alcoholism, the vast majority of Kolp’s patients (nearly 
90%) had concurrent addictions (e.g., to caffeine, 
sugar, nicotine, cannabis, benzodiazepines, opiates, 
and amphetamines), and about half had coexisting 
psychological problems (e.g., generalized anxiety 
disorder, social phobias, primary insomnias, acute and 
repeated stress disorders, pain disorder, panic disorder, 
depressive disorder, posttraumatic stress disorder, 
tension and migraine headaches, somatization disorder, 
and chronic fatigue syndrome). As with Krupitsky’s 
technique, Kolp’s treatment modality explicitly relied 
on the transpersonal effects of ketamine to facilitate 
psychotherapeutic change. Kolp experimented with 
several different courses of treatment with KPP, 
ranging from a time-limited individual treatment on 
an outpatient basis to an intensive 1 to 3 week group 
treatment in the framework of a residential program. 
Kolp summarized his empirical clinical observations 
on KPP effectiveness for treating alcoholism and other 
coexisting disorders in his first report (Kolp et al., 
2006).
 After gaining extensive experience with KPP 
for the treatment of alcoholism, Kolp extended the 
inclusion criteria for KPP and began accepting patients 
with other drug dependencies and food addiction. Kolp 
also started utilizing KPP for the treatment of end-of-life 
anxiety in patients with terminal illnesses. He continued 
utilizing group psychotherapy in a residential setting 
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for treatment of addictive disorders and coexisting 
psychological problems. In addition, Kolp continued 
utilizing individual psychotherapy on an outpatient 
basis for treatment of existential anxieties in terminally 
ill people and selected patients with addictive disorders 
who did not wish to participate in a residential treatment 
program, or could not tolerate a group process. 
During the second stage of his work with 
KPP (2000-2006), Kolp treated approximately 100 
patients with various addictive illnesses (primarily 
alcoholism, opiate dependence, and food addiction), 
concurrent psychological diseases (mainly anxiety and 
mood disorder, acute and repeated stress disorders, 
and psychosomatic disorders), coexisting personality 
disorders, and existential anxieties related to the end-
of-life issues. Kolp documented his empirical findings 
in a second report (Kolp et al., 2007). In addition, 
Kolp collaborated with Krupitsky and both authors 
published their combined experience and accumulated 
data on clinical research and empirical observation of 
the effectiveness of KPP (Kolp, Krupitsky, Friedman, & 
Young, 2009; Krupitsky & Kolp, 2007).
 During the third stage of his work with KPP 
(2007 through the present), Kolp continued treating 
patients with various addictive illnesses, concurrent 
psychological diseases, and coexisting personality 
disorders. He also started accepting for KPP selected 
clients who had already resolved their addictions 
and major psychological problems and were looking 
for growth-oriented psychotherapy and lifestyle 
optimization. 
 In addition, Kolp began treating patients 
with chronic treatment-resistant depression (TRD), 
which is presently defined as a failure to respond 
to an adequate trial with two or three conventional 
antidepressants. Interestingly, the vast majority of the 
patients with TRD were not psychologically minded 
and had no interest in KPP. Instead, they desired to 
undertake only pharmacotherapy with a low sub-
psychedelic dose of ketamine. In total, during the past 
7 years, Kolp administered KPP to approximately 150 
“psychologically-minded” clients with drug and food 
addictions, and ketamine pharmacotherapy to about 50 
“pharmacologically-minded” patients with treatment-
resistant chronic anxiety and/or depressive disorders.
 Kolp also administered KPP in the same 
3-stage format as was originally designed by Krupitsky: 
preparation, administration, and integration. Kolp 
always used a high psychedelic dose of ketamine (2.0 
mg/kg – 2.5 mg/kg IM, or 150 – 200 mg IM) in order to 
both avoid an OBE and to specifically induce the near-
death experience or, considered by Kolp as even more 
desirable, the ego-dissolving transcendental experience. 
Kolp disfavors an OBE for the same reasons that were 
previously discussed by Roquet and colleagues (1971, 
1975) and Yensen (1973): most of the time the OBE 
simply represents the patient’s wish fulfillment and the 
patient only runs from problems with pleasant fantasies. 
Although the OBE may resemble certain mystical states, 
the experience usually does not yield true insight and, 
in fact, may even have a negative effect on the ego, as 
illustrated by the following case study: 
C was a 52-year-old Caucasian female with a long 
history of binge alcoholism. She reported a stable 
childhood, with no history of physical or sexual 
abuse. C was raised as a Roman Catholic. However, 
she abandoned that denomination during her 
late teens, continuing as a non-denominational 
Christian.
C began using alcohol at age 16, started drinking 
on a regular basis at age 18, and developed alcohol 
binges at age 25. Her binges lasted from 3-4 days to 
2 weeks, every several weeks, with a consumption 
of nearly one liter of vodka a day during the binges. 
She undertook more than 10 various rehabilitation 
programs. However, she never had a stable remission 
(her longest remission lasted 7 months, including 
2 months in a rehabilitation program). C did not 
wish to participate in a group residential program 
and elected an individual outpatient treatment. 
In addition, she did not follow strict preparatory 
guidelines (a whole food plant based diet, optimal 
hydration, daily meditation and exercise, limitation 
of screen time, etc.). Moreover, she continued 
using sugar, caffeine, and nicotine throughout the 
preparatory stage. Although she received 150 mg 
of ketamine IM, her ego remained well-preserved 
and she did not experience EDT, or, at least, NDE. 
Instead, she had an OBE that she described as 
“paradisiacal”:
My mind left my body and I found myself in the 
Heaven … flying high above the silver and gold 
clouds … in the company of thousands of angels 
who were there to guide and protect me. The music 
was exceptionally lovely and we were ascending 
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higher and higher … eventually arriving into the 
Garden of Eden. The angels showed me the beauty 
of their home and then helped me to soar directly to 
the throne of Jesus. His presence overwhelmed me 
and I started crying and laughing at the same time. 
I felt the Jesus’ unconditional love and understood 
that all my sins were forgiven. He blessed me and I 
promised Him to never ever touch another drink of 
Vodka again. I then returned back into my body … 
feeling joyful and full of bliss … and I knew–with 
all my heart–that I got reformed forever. 
 She attended only one follow-up session and 
proudly reported that she had rejoined her church 
and started praying again on a daily basis. She insisted 
that her encounter with Jesus completely healed her 
from alcoholism and that she no longer needed to 
participate in an AA 12-step recovery program. C 
relapsed on alcohol 8 months later and committed 
suicide soon after the end of her 2-week binge.
Kolp quickly discovered that the OBE can 
be fascinating and gratifying for the ego, but it can 
sometimes have a rather low therapeutic potential outside 
of a long-term psychodynamic psychotherapy that 
requires repeated inductions of the OBE. Subsequently, 
Kolp’s primary goal has been to induce the ego-dissolving 
transcendental experience, or at least the near-death 
experience, since both the NDE and EDT experiences 
more frequently generate not only a complete resolution 
of the patient’s addictive illnesses and coexisting 
psychological problems, often after a single session, but 
may also cause instances of spontaneous healing from 
chronic psychosomatic illnesses (Fenwick & Fenwick, 
1995; Grey, 1985; Kolp et al., 2007, 2009; Krupitsky 
& Grinenko, 1997; Krupitsky & Kolp, 2007; Morse & 
Perry, 1992; Ring, 1980, 1984; Ring & Valeriano, 1998; 
Roud, 1990). In addition to its more specific healing 
potentials, the NDE and the EDT experiences may 
also rapidly accelerate patients’ psychospiritual growth, 
broaden their worldviews, and generate a spontaneous 
spiritual transformation with a dramatic improvement 
of moral character (Kolp et al., 2007; Krupitsky & 
Grinenko, 1997; Krupitsky & Kolp, 2007).
 The primary factors that greatly influence the 
likelihood of these desirable NDE and EDT experiences 
are the dose of ketamine, the mindset of an individual 
prior to the ketamine session, and the session’s setting. 
To reiterate, the mindset is the mental state that a person 
brings to the experience, such as thoughts, mood, 
personality structure, expectations, and worldviews. 
It is the most important part of KPP and basically 
stands for a rigorous preparation for the ketamine-
induced experience. The setting is also very important 
and includes physical (the room’s atmosphere) and 
social (feelings of the group’s participants towards one 
another and toward therapist/therapists) components. 
The social support network is particularly important 
in the outcome of the ketamine-induced NOSC. 
The group and/or a therapist are able to control and 
guide the course of the experience, both consciously 
and subconsciously. Anxiety prior to the experience or 
a disagreeable environment may induce a frightening 
experience. On the other hand, curiosity and a positive 
attitude, together with a comfortable and safe place, are 
more likely to generate a blissful experience.
 In addition to set and setting, the novelty of 
the psychedelic experience may be salient for successful 
problem resolution. Psychedelics are a unique class 
of drugs that produce intense effects unlike those of 
other drugs, and one’s first “trip” can therefore be a 
profound and life-changing experience (as common 
wisdom says, “there is no second chance for the first 
impression”). Consequently, for those with extensive 
histories of psychedelic use, there is a diminished chance 
that a ketamine experience will be all that unique and 
transformative (“just another trip”), whereas for the 
novice psychedelic user, given proper mindset and 
setting, the experience can be profound. 
 Kolp believes that the most influential 
component of a successful KPP (in addition to dose, 
set, and setting) that can greatly increase the odds of 
the optimal EDT experience is vigilant preparation prior 
to the ketamine administration. Without a careful and 
laborious preparation, only about half of the patients 
may have an NDE (even with a dose of ketamine that 
is set to cause a near-death experience) and only 1 out 
of 20-25 patients may have an EDT experience. By 
attentively preparing the patients for a ketamine-induced 
experience through creating the spiritually-oriented 
mindset (as well as carefully controlling the setting), the 
likelihood of having an NDE becomes nearly universal. 
Meanwhile, the likelihood of an EDT experience can be 
increased from only 1 out of 20-25 patients to 3-4 out of 
10 patients. Unfortunately, the EDT experience is very 
elusive and there is no guarantee of the EDT occurrence 
even with the most arduous preparation. 
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 Whether the patient elects to participate in 
a residential group program or outpatient individual 
treatment, Kolp starts the preparatory period 6 weeks 
prior to the induction of the ketamine experience. 
During those 6 weeks, all patients participate in weekly 
group psychotherapy (unless the patient does not want a 
residential treatment, or cannot tolerate a group process; 
in that case the patient is engaged in a weekly individual 
psychotherapy). During the same 6 weeks, Kolp strongly 
encourages all patients to prepare the body and mind 
through partial fasting following a whole food plant based 
(WFPB) diet, optimal hydration, de-stressing through 
daily meditation, contemplation on the nature of the Self 
and God, limitation of “screen” time, and daily exercise. 
Kolp further suggests de-toxifying the body from all 
sedatives (such as sugar, alcohol, benzodiazepines, and 
opiates) due to their tendency to dull the mind and all 
psychostimulants (such as caffeine, nicotine, ephedrine, 
amphetamines) due to their tendency to aggrandize the 
ego.
 In the experience of Kolp, fasting is a key aspect 
of the more acute preparatory process. The reasons why 
this is of assistance to the outcome remain speculative, 
but fasting has long been a part of the spiritual quest 
in many cultures and religions because it seemed to 
weaken the ties of the physical body to the material 
realm. Fasting can be total, abstaining from all food and 
beverages apart from water, or it can be partial. Kolp 
never asks patients to undergo a total fast. However, he 
highly recommends a partial fast and suggests abstaining 
prior to the ketamine session from highly refined simple 
carbohydrates (all sugary drinks such as soda pop and 
fruit juices, chocolate, doughnuts, cookies, cake, candy, 
etc.), highly processed complex carbohydrates (white 
bread, rolls, pasta, white rice, French fries, etc.), dairy 
products (milk, yogurt, sour cream, butter, cheese, ice 
cream, etc.), fatty “rich” foods (steak, bacon, salami, 
pastrami, hamburgers, cheeseburgers, etc.) and “junk” 
foods (chips, pretzels, crackers, pizza, etc.). Participants 
are encouraged to follow the WFPB diet, getting the 
majority of calories from vegetables, with some calories 
coming from certain whole grains, legumes, fruits, and 
nuts. During the fasting period, optimal hydration is 
strongly recommended by drinking one glass of water 
(no carbonated, caffeinated, or sugary drinks of any 
kind) every 2-3 hours during wakeful time. 
 To calm and prepare the mind, Kolp 
recommends taking a time out for daily meditation or 
mindfulness sessions. Ideally, participants would take 
twenty to thirty minutes each day for this practice. 
However, even ten to fifteen minutes daily is beneficial. 
Kolp also recommends spending fifteen to twenty 
minutes every day contemplating on the nature of the 
Self and the nature of whatever the person understands 
by the word “God” or the connectivity between the Self 
and the rest of the Universe, or a Higher Power as in 
the 12-step programs. Many participants find it helpful 
to keep a journal during this time to document their 
progress, including any regressions, in order to stay on 
track during this phase. 
 In addition, Kolp strongly advises de-stressing 
the mind by limiting “screen” time beyond that which is 
required for each individual participant’s employment. 
Recreational screen time should be limited to less than 
two hours daily. Screen time includes, but is not limited 
to, computer use, watching television, playing video 
games, watching movies, and using smartphones. 
 Exercise is recommended at least five days a 
week for a period of forty-five to sixty minutes at a time. 
Kolp recommends low impact isotonic exercises such as 
deep stretching or yoga; however, any type of exercise is 
beneficial. 
 Although the preparatory guidelines may seem 
strict, this conscious preparation of the body, mind, 
and spirit prior to the administration of ketamine is 
seen by Kolp as increasing the likelihood of having 
either a classic NDE or distinct EDT experience. 
In Kolp’s experience, after a detailed, vigilant, and 
focused preparation, almost 50% of participants have 
a classical NDE and nearly 35% participants have a 
highly desirable EDT experience. Unfortunately, even 
with the most arduous preparation, approximately 
15% of participants still have a standard OBE. Most 
of them are the patients who had a very high tolerance 
to sedatives (e.g., sugar, alcohol, benzodiazepines, 
barbiturates, and opiates), severe control issues (they 
are simply unable or unwilling to surrender to the 
existential or transpersonal experience), persistent 
difficulties in maintaining long-term interpersonal 
relationships, and those with dogmatic beliefs in an 
authoritative or critical God.
  After 6 weeks of an outpatient preparation and 
detoxification as well as 6 weekly psychotherapy sessions, 
the patients are placed in a structured residential setting 
for the second stage of treatment—the administration of 
ketamine-induced non-ordinary states of consciousness. 
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The length of a residential component varies from 1 
week (growth-oriented program) to 3 weeks (addiction 
rehabilitation program). The one-week growth-oriented 
residential program offers 30 hours of psychoeducational 
and encounter groups, existential and transpersonal 
group psychotherapies, and interactive classes and 
didactic lectures. The three-week rehabilitation program 
for the treatment of food and drug addiction provides 
the same 30 hours of analogous psychoeducational and 
encounter groups, existential and transpersonal group 
psychotherapies, and interactive classes and didactic 
lectures. In addition, it provides another 60 hours of 
various life skills training such as communication skills, 
problem solving skills, relapse prevention, relationship 
skills, anger management, and decision-making, as 
well as training in optimal lifestyle and advising health 
issues, nutrition education with food purchase and 
preparation, non-verbal therapies, such as art therapy 
and music therapy, in order to provide the patients with 
alternative means of self-expression, problem resolution, 
and motivational enhancement. Those patients who opt 
out of a residential component of a treatment program 
receive the administration of ketamine in an outpatient 
setting, without the benefits of an intense group process 
of a residential program.
 Whether ketamine administration is performed 
in an outpatient office, or in a residential center, Kolp 
recommends both settings have comfortable, scenically 
pleasant, home-like atmospheres. Breakfast is omitted 
on the morning of ketamine administration, and all 
participants refrain from food and drink from midnight 
through the ketamine-induced experience. The ketamine 
solution is administered via a brief intramuscular 
injection, rather than an intravenous administration 
requiring the use of an IV line, adding to the comfort 
of each patient. After the injection, the patient wears 
eyeshades, is instructed to fully surrender to the ketamine-
induced experience, and beautiful, evocative music starts 
playing to assist with relaxation and immersion into the 
experience. 
 The NOSC lasts from 45 minutes to an hour 
under these conditions and then the patient slowly comes 
back from the experience. During the recovery period, 
which takes from one to two hours, the background 
composition changes from a free-floating non-associative 
music to an inspirational guided imagery meditation to 
affirm the patient’s sought after transformation. When 
patients returns to an ordinary state of consciousness, 
they are asked to describe the experience, and some 
limited discussion and interpretation is begun with the 
psychotherapist. After the session, the patient goes to 
rest and is asked to write down a detailed self-report of 
the ketamine-induced transpersonal experience during 
the second part of the day. 
 The integration of a ketamine-induced experience 
starts on the evening after the ketamine session and 
continues throughout the rest of the residential program. 
After the end of a residential component of the treatment, 
all patients continue weekly group psychotherapy 
sessions on an outpatient basis for 3 additional weeks. 
The patients who elect to participate in an outpatient 
individual treatment also receive 3 weekly individual 
psychotherapy sessions during the integration part of the 
treatment. Afterward, Kolp provides follow-ups every 6 
months for all patients treated with KPP for as long as 
they continue to participate in aftercare.
 With these in depth, challenging preparatory 
and aftercare guidelines, Kolp was able to increase the 
effectiveness of KPP from 70% reported by Krupitsky 
(1992, 1997) to approximately 85% previously reported 
by Roquet (1975) and Yensen (1985). So far, the longest 
observed remission has been for 12 years (the patient 
undertook a 3-week residential treatment program in 
2002), as illustrated by the following case study: 
B was a 47-year-old Eurasian male who identified 
himself as a food addict. He reported no childhood 
trauma and described his nuclear family as very 
loving and supportive. B was raised as a Methodist, 
but changed his religious identification to a non-
denominational Christian during his late teens and 
eventually began identifying himself as “spiritual 
but not religious” during his early 30s. He described 
himself as a “steak and potato man” and was proud 
of himself for never having a dessert. B had 6 feet 4 
inches height and 220 pounds weight by age 18 and 
remained very fit throughout his mid-20s due to a 
very strenuous athletic involvement (a football player 
in high school and 6 years of active duty service in 
the Marine Corps). After an honorable discharge 
from the armed forces at the age of 26, he became 
employed as a manager of a fast food restaurant. 
 B described himself as a compulsive overeater, 
who never attempted to compensate for his bingeing 
with purging behaviors such as fasting, laxative use, 
or vomiting. He did exercise a good deal through his 
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early 30s. However, he eventually stopped working 
out and developed a sedentary lifestyle. In addition, 
he became engaged in “grazing” behavior and started 
picking at food throughout the day. 
 B’s food preference was for fats and flour 
products, which he consumed three times a day, in 
addition to snacking between his major meals. His 
tolerance slowly increased and by his late 30s, his 
typical breakfast consisted of one 8-ounce sirloin 
steak, two big baked potatoes with sour cream, 4 
scrambled eggs, a couple of sausages or 2 slices of 
ham, and a half dozen biscuits with butter. His 
lunch and dinner were equally impressive, always 
including large amounts of meats, bread, and 
butter. In addition, B had 3-4 self-made sandwiches 
between his main meals, which he prepared from a 
slice of ham or bologna meat, a slice of cheese, and 
2 slices of white bread with butter. Once a month 
he treated himself with a 30-ounce strip sirloin at 
a steak house. B was a participant in an April 2000 
survey, who would not give up meat for a week even 
if he were paid a thousand dollars to do so.
 By the age of 40, B’s weight reached 300 pounds. 
He was already diagnosed with hypertension, type 
II diabetes, hyperlipidemia, osteoarthritis, and sleep 
apnea. He had to take eight medications a day and 
his primary physician repeatedly warned him that 
he was a few years away from a stroke or a heart 
attack. At that point B started taking some action 
and began dieting, but always unsuccessfully. He 
would stay on a diet of the season for a few weeks and 
sometimes drop several pounds in weight. However, 
each time he resumed his compulsive overeating. 
 B joined Overeaters Anonymous (a 12-step 
recovery program based on the principles of Alcoholics 
Anonymous, which is also known as The Fellowship) 
at age of 42, but left the program after a year (“too 
much praying, but no spiritual awakening”). He also 
briefly tried Food Addicts in Recovery Anonymous 
(an alternative 12-step based program) and had no 
problems with completely abstaining from sugar, 
but could not abstain from the flour products 
longer than several weeks. In addition, he resented 
weighing and measuring all his meals and could not 
abstain from snacking between meals. B undertook 
a sleeve gastrectomy at age of 44, which helped him 
to decrease his weight to 250 pounds. However, he 
managed to “re-feed” himself within 2 years after the 
surgery. By the time he applied for treatment with 
KPP his weight was 310 pounds.
 B was willing to stop eating meat and dairy 
products for 6 weeks prior to a ketamine session 
and agreed to abstain from highly refined and/
or highly processed food for the same period of 
time. He reported severe cravings for fats and flour 
during the first 3 weeks. However, he was able to 
remain abstinent from the prohibited items. B 
actively participated in all groups, meditated twice 
a day, and started walking for 30 minutes every 
other day. Unbeknown to his therapist and the 
group, B sneaked out of the residential facility the 
evening prior to the administration of ketamine in 
order to have his “last supper,” a veal parmigiana 
dish. The following morning B received 250 mg of 
ketamine IM and had a very frightening NDE that 
he described as “hellish”:
I got out of the body and initially rejoiced the 
freedom of leaving my fat and sick body. Within a 
minute or two though my mind started dissipating 
and it scared me very much. I remember thinking: 
I am really dying … it is the end of my life … oh, 
no, no … please make it stop. The mind completely 
gone and all that remained was a soul … silent, 
sad and lonely … rapidly falling into the abyss 
of nothingness. At some point the movement ... 
stopped and the soul became motionless in the 
middle of the void. All of the sudden, my entire 
life began getting replayed and the soul was 
despondently observing my Earthly life of a glutton 
… a hungry sponge devouring countless living 
beings out of a lust for taste. The feeling of sorrow 
became resilient and the last conscious awareness 
was terrifying—if the Hell and the Heaven do, in 
fact, exist, the soul definitely belongs to the Hell. 
As soon as my soul came to this conclusion, 
it got immediately sucked deep into an infinite 
ocean of unconditional sorrow and became that 
veal calf … taking away from the mother … 
suspended in a stall … restricted in movements … 
without seeing a sky and the trees … sensing that 
something is terribly wrong … that it is not how 
life is supposed to be lived … tormented and very 
miserable … finally going through a cruelty of a 
slaughterhouse … hanged upside down … skinned 
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while still being alive. The soul’s suffering became 
repetitive … re-living life of all animals that my 
body consumed and my mind adored … again and 
again … life after life … with no end at all. It 
seemed like the soul has been tortured for thousands 
if not millions of years before the mind re-emerged 
and then re-entered the body. My whole essence 
was screaming —no more carnivorous lifestyle 
… no more causing suffering and death to God’s 
innocent creatures.
 B has continued to conscientiously participate in 
aftercare since the completion of his treatment and 
completely abandoned eating any animal products, 
both meat and dairy. He continued meditating daily 
and restarted exercising on a regular basis. B did not 
give up eating biscuits and potatoes (no butter and no 
sour cream), but he started limiting the consumption 
of flour and starches to once a week, eating only two 
biscuits and one potato on the weekends. Within 2 
years, his weight stabilized at around 200 pounds 
and has remained constant since. The number of 
the medications has decreased from 8 to 1 and his 
hypertension, type II diabetes, hyperlipidemia, and 
sleep apnea have completely resolved. 
Although the above case is rather exceptional, the vast 
majority of the patients treated with KPP do develop 
a stable remission, lasting from 2-3 to 5-7 years and 
longer. Kolp, like Krupitsky before him, has repeatedly 
observed a dramatic improvement in patients’ overall 
bio-psycho-socio-spiritual functioning, including rapid 
optimization of a personal lifestyle, decreased levels of 
inner conflicts and emotional isolation, enrichment 
of interpersonal relationships, resolution of existential 
death anxiety, positive changes in the life values and 
purposes, broadening of the worldviews, and acceleration 
of psychospiritual growth, through his approach to KPP.
Possible Mechanisms 
of the Effectiveness of KPP 
Krupitsky previously reported that ketamine increases delta and theta activity in the cortex, evidencing 
limbic system activation as well as limbic-cortex 
interaction (Krupitsky & Grinenko, 1997). It was further 
documented that ketamine exerts its effect through 
a functional and electrophysiological dissociation or 
disconnect between the thalamo-neocortical and limbic 
areas of the brain (Green & Krauss, 2004a, 2004b; 
Mistry & Nahata, 2005).
 Therefore, the Russian group including Kolp 
hypothesized that ketamine’s underlying mechanism 
of action on the brain is the blockade of the thalamo-
cortical projections and the activation of the interactions 
between frontal cortex and limbic structures, which 
results in a specific hyperfrontal metabolic pattern in 
the human brain, associated with ketamine-induced 
psychedelic experience (intense visionary experience and 
ego-dissolution). The thalamus’ primary function is to 
relay sensory and motor signals to the cerebral cortex; the 
frontal cortex is responsible for cognitive processing of 
information (conscious mind); and the limbic system is 
the brain’s center of emotions (unconscious mind). Thus, 
ketamine blocks transmission of incoming signals from 
all sensory modalities, including signals from the outer 
world and one’s own body, and reinforces the interactions 
between the so-called cognitive and emotional minds. In 
other words, ketamine appears to disconnect the self from 
so-called objective reality, ties self-aware and unaware 
levels of mind in a closed loop, and removes a filter 
between conscious mind and unconscious mind, resulting 
in a profound waking dream that bears a remarkable 
resemblance to OBE, NDE, or EDT experiences. 
The ketamine-induced non-ordinary states of 
consciousness seem to generate a different level of self-
identification. Kolp describes that as, during OBEs, 
self-identity switches from “I am Body” to “I am 
Mind,” while during NDEs the self-identity becomes 
more similar to “I am Soul” and during the EDTs 
more like Unio mystica or mystical union in which self-
identity further progresses to “I am God.” At no time, 
of course, is it suggested in KPP that the Soul and/or 
God experiences constitute any proof of the existence 
of any specific theological concept.  These psychedelic 
experiences are subjective phenomena that cannot be 
easily, if ever, scientifically objectified, and they certainly 
do not prove the existence of any transcendental reality. 
Nevertheless, for reasons that remain speculative, having 
the uniquely profound and powerful mystical experience 
can significantly contribute to broadening attitudes about 
the self and the world, positive changes in life values and 
purposes, resolution of existential death anxiety, and 
rapid acceleration of spiritual transformation. 
 In 1962, Pahnke (1962, 1968, 1969; Pahnke et 
al., 1970) conducted the double-blind “Marsh Chapel 
Experiment” (a.k.a. the “Good Friday Experiment”) 
investigating whether a psychedelic agent (psilocybin) 
would cause a genuine mystical experience in religiously 
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predisposed subjects. Virtually all members of the 
psilocybin group (graduate degree divinity students) 
reported having profound religious experiences and the 
faculty of the Harvard Divinity School concluded that 
a psychedelic agent can indeed facilitate such mystical 
experiences.
 Twenty-five years later, Doblin (1991) traced 
seven theological seminary students participating in 
the Good Friday Experiment and reported that all of 
the psilocybin subjects continued considering that their 
original religious experience had a genuineness in terms 
of mystical nature and characterized it as a high point of 
their spiritual lives. One of these students was religious 
scholar Huston Smith, an author of several textbooks 
on comparative religion, who later on described his 
original psychedelic experience as the most powerful 
homecoming he had ever experienced (Smith, 2001).
 In 2002, a group of investigators at Johns 
Hopkins University conducted a more rigorously 
controlled study similar to the Good Friday experiment 
(Griffiths et al., 2006). The study’s participants were 
hallucinogen-naïve adults who reported regular 
participation in religious or spiritual activities. The study 
compared psilocybin (30 mg) and methylphenidate (40 
mg) using a double-blind between-group, crossover 
design. Thirty volunteers received 30 mg of psilocybin 
and 40 mg of methylphenidate in counterbalanced 
order. Two or three sessions were conducted at 2-month 
intervals. To obscure the study design, 6 additional 
volunteers received methylphenidate in the first 2 
sessions and un-blinded psilocybin in a third session. The 
8-hour sessions were conducted individually. Volunteers 
were encouraged to close their eyes and direct their 
attention inward. The study’s investigators documented 
that 67% of the participants who received psilocybin 
experienced powerful NOSC that had similarities to 
naturally occurring mystical experiences. Furthermore, 
those drug-induced mystical experiences were rated 
by volunteers as having great personal and spiritual 
significance that resulted in sustained positive  attitudes 
and behavior that were corroborated by ratings from 
friends and family.  
Sixteen months later, the same group of 
researchers at Johns Hopkins University completed a 
follow-up to their original psilocybin study (Griffiths et 
al., 2008). Two thirds of the study participants continued 
rating the psychedelic-induced experience as among 
the top most meaningful experiences in their lives. 
Sixty-four percent of the participants reported that the 
experience increased well-being and life satisfaction, and 
58% met criteria for having had a “complete” mystical 
experience. Seventeen percent indicated that it was the 
most meaningful and significant experience, while none 
of the participants rated the experience as leading to 
decreased well-being or life satisfaction. The researchers 
concluded that the mystical aspect of the experience was 
crucial in achieving positive therapeutic outcomes, and 
they recommended additional therapeutic trials with 
hallucinogens.
 Kolp thinks it is evident that an ego dissolution 
during psychedelic-induced mystical (transcendental, 
spiritual) peak experience is perceived by healthy 
volunteers and mentally ill patients alike as transcending 
their individual body restrictions and generates a 
psychological sense of security which extends beyond the 
impermanence of the finite corporeal body. Successively, 
the individuals can better cope with the prospect of 
the yet to come death and demonstrate a long-lasting 
resolution of existential death anxiety (Cohen, 1965; 
Griffiths et al., 2006, 2008; Grinspoon & Bakalar, 
1979; Grob, 1998, 2002; Grof, 1978, 1980, 1986; 
Grof & Halifax, 1976; Grof et al., 1973; Kast, 1966a, 
1966b; Kast & Collins, 1964; Kolp et al., 2007, 2009; 
Krupitsky & Grinenko, 1996; Krupitsky & Kolp, 2007; 
Krupitsky et al., 1992; Pahnke, 1968; Pahnke et al., 
1970; Richards et al., 1972, 1977, 1979; Walsh & Grob, 
2005; Watts, 1973; Yensen & Dryer, 1993/1994).  The 
following case study demonstrates the efficacy of ego-
dissolving transcendental experience in the treatment of 
a patient with chronic depression, recurrent headaches, 
and combined opioid and barbiturate dependence: 
M was a 34 year-old Hispanic American female 
who had been suffering from chronic depression 
since her puberty. In addition, she developed the 
onset of recurrent headaches within 2 years after the 
commencement of her marriage at the age of 22. 
She was raised as a non-denominational Christian 
and changed her self-identity to “spiritual but not 
religious” during her early 20s. She reported no 
history of physical and/or sexual abuse during her 
childhood, but acknowledged a long history of an 
ongoing repeated stress due to a hapless marriage 
(she described her husband as a “patriarchal male 
chauvinist pig”), 2 children of ages 11 and 9 with 
conduct disorder and ADHD (whom she referred to 
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as “little terrorists”), and a demanding full-time job 
with an “awful boss.” 
 M began psychiatric treatment at the age 
of 16 and and had already been prescribed 
many antidepressants, including five SSRIs 
(fluoxetine, paroxetine, sertraline, citalopram, and 
escitalopram), three SNRIs (venlafaxine, duloxetine, 
and desvenlafaxine), one NRI (bupropion) and one 
NaSSA (mirtazapine). Although she responded well 
to the treatment with her first SSRI and first SNRI 
(both times the remission lasted for 9 and 6 months 
respectively), the efficacy of antidepressant treatment 
eventually became marginal. M also started 
treatment with a neurologist at the age of 24 and 
was treated with several anti-migraine medications, 
including sumatriptan, metoprolol, topiramate, 
gabapentin, rizatriptan, and pregabalin, all with 
limited results. 
 At the time of her initial evaluation for KPP 
treatment, M was taking a combination of bupropion 
(300 mg in the morning), mirtazapine (45 mg at 
bedtime), and Fioricet (codeine 30mg, butalbital 
[a barbiturate] 50mg, acetaminophen 300mg, and 
caffeine 40mg) which she took as 2 capsules 4 times 
a day (240 mg of codeine and 400 mg of butalbital 
daily). She continued complaining of chronically 
depressed mood (she scored 28 points on the Beck 
Depression Inventory) and recurrent headaches (3–4 
times a week, lasting for several hours). 
 M elected to participate in a group residential 
program and agreed to get detoxified from both 
sedatives (codeine and butalbital) and both 
antidepressants (bupropion and mirtazapine) since 
her medications “did not work anyway.” In addition, 
she dutifully followed strict preparatory guidelines 
(a whole food plant-based diet, optimal hydration, 
daily meditation and exercise, limitation of screen 
time, and contemplation on the nature of the Self and 
God). After successful preparation on an outpatient 
basis, M was admitted to a residential program 
where she became actively engaged in an intensive 
group process. She received 150 mg of ketamine IM 
and reported the following EDT experience:
My body became dissolved as an icicle in a hot 
water and my mind began steadily expending 
as an inflating balloon. First, I got aware of the 
surrounding space around me and actually became 
the growing trees … and birds … and animals 
… and other people … in the range of 300-400 
yards around me. This expansion did not stop at 
it and my mind continued progressively getting 
larger and larger … until it embraced the entire 
Earth and I became aware that I am a part of the 
Great Mother Gaia. At that point my individual 
mind disappeared and became transformed into 
collective mind. The collective mind continued 
rapidly expending to the entire Solar system 
… then to the entire Milky Way galaxy … and 
eventually to the entire Universe. The individual 
awareness shifted to the awareness of the Universal 
Mind and my personal Soul became a part of the 
Universal Consciousness. God and I are One and 
We are omniscient, omnipotent, omnificent and 
omnipresent. The experience seemed lasting for the 
eons … and all that time the awareness remained 
“everything is exactly as it should be” … “We are 
all One” … “everything is perfect” … “everything 
is perfect” … 
M continued in aftercare for 2.5 years until she and 
her family relocated to another state. She reported 
that her chronic depression had finally resolved 
and her recurrent headaches were completely gone. 
M also became actively engaged in ongoing family 
psychotherapy and reported marked improvements 
in her relationships with her husband and children, 
as well as improvements in her other interpersonal 
relationships. She continued exercising and 
practicing meditation on a regular basis, stopped 
consuming animal products, and began volunteering 
in a local charity. 
M’s case represents a typical KPP treatment outcome 
among those patients who experienced an ego-dissolving 
mind-expanding transcendental experience.
Antidepressant Effects of Ketamine
The low dose of ketamine used for analgesia and anxiolysis as well as the medium dose of ketamine 
used for conscious sedation can reliably produce brief 
but robust antidepressant effects. Various investigators 
started publishing reports documenting antidepressant 
effects of ketamine in the early 1970s. These earlier 
studies, performed from the 1970s through the 1990s, 
utilized ketamine in medium doses and generally 
attributed anxiolytic/antidepressant responses to an 
overall psychological improvement following the 
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induction of NOSC, a specific phenomenon called 
“psychedelic afterglow.” This psychedelic afterglow state 
consists of positive physical and psychological changes, 
including increased psychological clarity, feelings 
of being cleansed, increased confidence, feeling of 
happiness and well-being, state of inner peace, feelings 
of detachment, motivation to improve oneself, and 
strong feelings of empathy for everyone. The afterglow 
state was thought to be induced by the psychedelic 
peak experience and reported to last from several days 
to several weeks and longer (Adamson, 1985; Bolle, 
1985, 1988, 1992; Grossbard, 1989; Fontana, 1974; 
Khorramzadeh & Lofty, 1976; Krupitsky, 1993/1994; 
Krupitsky & Grinenko, 1996, 1997, 1998; Krupitsky 
et al., 1992; Moore & Altounian, 1978; Roquet, 1975; 
Roquet & Favreau, 1981; Roquet et al., 1971; Yensen, 
1973).
 However, it was also long recognized that 
ketamine was likely to acutely improve mood secondary 
to its effects on, for example, the dopamine system, 
which have some commonalities with amphetamine 
and cocaine, and there was certainly long-standing 
speculation as to a neurochemical basis for ketamine 
improving mood for up to a week, with lack of a post-
stimulant crash being attributed to such possibilities as 
the lingering presence of active ketamine metabolites 
and/or gene induction (summarized in Jansen, 2001.) 
In this context, it is of note that the original Maudsley 
monograph describing amphetamine psychosis warned 
against attributing mental state changes to anything 
other than amphetamine while the metabolites could 
still be detected in the urine, and that the metabolites 
could sometimes be detected for at least a week (Connell, 
1958), as is sometimes the case with ketamine.
The general trend changed with a formal study 
done by Krystal’s group of investigators who reported 
that research subjects with symptoms of depression 
showed a dramatic antidepressant response to an 
administration of low sub-psychedelic doses of ketamine 
(Berman et al., 2000). It is interesting to note that the 
original purpose of this study was not to research the 
antidepressants effects of ketamine but to assess its 
cognitive effects on subjects with mental illness. The 
antidepressant effect of ketamine was apparently not 
expected by this group (Brown, 2007). Some similar 
studies have replicated these findings and confirmed that 
low doses of ketamine can produce a rapid antidepressant 
effect lasting from 1-2 days to 1-2 weeks (Kudoh et al., 
2002; Ostroff, Gonzalis, & Sanacora, 2005). These 
results would probably not have been a surprise to most 
non-medical and “recreational” users of the drug, who 
have long reported elevation in mood for up to a week 
(summarized in Jansen, 2001). 
 These earlier reports seemed to have only a 
limited impact until a study was conducted at the 
National Institute of Mental Health (Zarate et al., 
2006). This randomized controlled trial was specifically 
conducted in subjects with TRD, including some 
patients who had not responded to electroconvulsive 
therapy. The study provided evidence that a single sub-
anesthetic dose of ketamine may provide rapid but non-
sustained relief of depressive symptoms. 
 Since publication of this study, further reports 
have confirmed the efficacy of ketamine for the treatment 
of major depressive disorder and the depressive phase 
of bipolar disorder (aan het Rot et al., 2010; Bjerre & 
Fontenay, 2010; DiazGranados et al., 2010; Ibrahim et 
al., 2012; Liebrenz et al., 2007, 2009; Murrough et al., 
2011, 2012; Rasmussenet et al., 2013; Rot et al., 2008; 
Zarate et al., 2012, 2013). Most recent studies have 
used a low sub-psychedelic dose of ketamine (0.5 mg/
kg) administered via IV infusion over 40 to 60 minutes 
(aan het Rot et al., 2010; Bjerre & Fontenay, 2010; 
DiazGranados et al., 2010; Glue, Gulati, Le Nedelec, 
& Duffull, 2011; Ibrahim et al., 2012; Liebrenz et al., 
2007, 2009; Murrough et al., 2011, 2012; Rasmussen 
et al., 2013; Rot et al., 2008; Zarate et al., 2006, 2012, 
2013), and one study utilized a low sub-psychedelic dose 
of ketamine (1 mg/kg) via IM administration (Glue et 
al., 2011). The number of ketamine administrations has 
varied from one to six (aan het Rot, Zarate, Charney, & 
Mathew, 2012). 
There are also reports documenting the 
effectiveness of ketamine pharmacotherapy in the 
treatment of eating disorders (Mills, Park, Manara, & 
Merriman, 1998) and obsessive-compulsive disorder 
(Rodriguez et al., 2013). Murrough and colleagues 
examined the efficacy of repeated ketamine infusions 
on the length of post-treatment remission (Murrough 
et al., 2012). The study’s subjects underwent a washout 
of antidepressant medication followed by up to six IV 
infusions of ketamine (0.5 mg/kg) administered three 
times per week over a 12-day period. Seventy-one 
percent of the patients developed a remission. However, 
the median time to relapse after the last infusion of 
ketamine was only 18 days. Some researchers have thus 
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been adopting a maintenance strategy (Messer & Haller, 
2010). There have been reports of oral (Irwin & Iglewicz, 
2010; Paslakis, Gilles, Meyer-Lindenberg, & Deuschle, 
2010) and sublingual (Lara, Bisol, & Munari, 2013) 
ketamine as an effective maintenance antidepressant. 
Since intranasal ketamine has been already used as an 
effective maintenance sedative and analgesic (Bahetwar, 
Randey, Saskena, & Chandra, 2011; Reid, Hatton, & 
Middleton, 2011), this technique is also being developed 
as both an initial and maintenance treatment of major 
depression (Lapidus et al., 2014). These 3 modalities—
oral, sublingual, and intranasal—are emerging as the 
preferred delivery methods of a ketamine maintenance 
treatment. 
 It is unknown how many persons who take non-
prescribed ketamine (i.e., non-medical and recreational 
users) are actually taking the drug to self-medicate what 
amount to depressive disorders. It is also unknown 
how many clinical practitioners in the United States 
have administered ketamine to patients with TRD, 
but general correspondence suggests a marked increase. 
An internet search identified an on-line organization 
(Ketamine Advocacy Network; KAN) that has a list 
of “ketamine doctors” in the United States who are 
performing the ketamine administration procedure 
(www.ketamineadvocacynetwork.org). At the time of 
writing this paper, KAN was listing 17 physicians from 3 
specialties, including 10 psychiatrists, 5 anesthesiologists, 
and 2 neurologists. All physicians are providing both the 
initial infusion of ketamine to rapidly relieve depression 
and a maintenance therapy to lengthen a remission 
after the symptoms of depression re-emerge. Sixteen 
physicians administer IV infusions of ketamine, and 1 
psychiatrist administers IM injections. One psychiatrist 
is offering a post-infusion maintenance treatment with 
transcranial magnetic stimulation, one anesthesiologist is 
offering maintenance treatment with intranasal and oral 
ketamine, and one neurologist is offering an intranasal 
maintenance treatment.
It is understandable why the majority of known 
ketamine providers have used IV infusions. All initial 
research studies that reported a robust anti-depressant 
effect of ketamine were using IV infusions of ketamine. 
However, IV infusions are partly the preferred delivery 
methods in a research setting because an IV line provides 
access for collecting blood samples to measure various 
biochemical markers before, during, and after the 
procedures. Outside the research setting, IV infusions 
may offer no particular advantage, and seem unlikely 
to be more beneficial than IM injections. This fact was 
emphasized by the initial group of formal researchers 
(aan het Rot, Zarate, Charney, & Mathew, 2012), who 
pointed out that previous research documented that 
IV administration of conventional antidepressants did 
not support increased efficacy over oral administration 
(Moukaddam & Hirschfeld, 2004).
 From the viewpoint of a physician practicing 
in a clinical setting, the IV infusions have many 
disadvantages. They are supposed to be performed 
in a hospital setting and to require the presence of an 
anesthesiologist, decrease the duration of therapeutic 
NOSC from 45-60 minutes to 20-25 minutes (unless 
performed as a continuous drip), and can increase the 
procedure’s cost to the patients from approximately 
$400 per IM administration to around $2,000 
per IV infusion, or more. Meanwhile, ketamine 
administration for treatment of mental illnesses remains 
an “experimental” procedure and its cost is not yet being 
covered by any medical insurance company, forcing 
non-research patients in the United States to bear the 
cost. In addition, IV infusions needlessly medicalize the 
procedure and, consequently, may increase the chances 
of a frightening experience. It has been suggested that 
IV ketamine infusions should perhaps be reserved for 
emergency room treatment only, where acutely suicidal 
depressed patients frequently present themselves (Larkin 
& Beautrais, 2011), although it is likely that even in 
this context, IV will eventually be shown to have no 
powerful advantage over IM when all the costs and 
benefits are weighed, as has gradually been demonstrated 
in psychiatric ICU hospital practice for benzodiazepines 
and antipsychotics, in which context giving the 
medicines as an IV injection is fading away in English-
speaking countries (e.g., Taylor, Paton, & Kapur, 2012).
 Other practitioners have already started 
utilizing IM injections of ketamine as the preferred 
treatment. A leading article in the January 2013 issue of 
Psychiatric Times (Kaplan, 2013) described a ketamine 
treatment program at the University of California San 
Diego (UCSD) Medical Center, directed by David 
Feifel, an associate professor in the Department of 
Psychiatry. Feifel recommended starting with the initial 
infusion to assess the length of a remission. Those 
patients who demonstrate at least one week of a stable 
remission are then referred for a maintenance treatment 
with repeated administrations of a low intramuscular 
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dose of ketamine (0.5 mg/kg) and no more frequently 
than once every 2 weeks. Feifel has begun utilizing an 
IM administration because of its practicality and cost 
effectiveness. He shared that when the UCSD program 
first started, anesthesiologists were required to give the 
intravenous ketamine infusions in an acute care setting, 
with the costs of IV procedures around $2,000 per 
infusion; in contrast, IM administrations are now given 
by nurses, with an attending physician available during 
the procedure, and the cost went down significantly 
(Kaplan, 2013). 
 Ketamine psycho-pharmacotherapy is rapidly 
gaining momentum. The FDA awarded the breakthrough 
therapy designation for the development of intranasal 
ketamine for treating depression (a definition of 
breakthrough therapy is a drug that treats a serious or 
life threatening disease and preliminary clinical evidence 
indicates that the drug may demonstrate substantial 
improvement over existing therapies on one or more 
clinically significant endpoints, such as substantial 
treatment effects observed early in clinical development). 
If a drug is designated as breakthrough therapy, the FDA 
will expedite the development and review of such a drug. 
All requests for breakthrough therapy designation will 
be reviewed within 60 days of receipt, and the FDA will 
either grant or deny the request. This is the first time this 
special designation, usually reserved for drugs targeting 
a lethal epidemic or a deadly form of cancer, has been 
awarded for the development of a medication for a 
mental disorder.
 A key remaining question is the duration of 
ketamine’s effect, which significantly varies not only 
from person to person, but also from treatment to 
treatment for the same person. At times, the effect only 
lasts a day or two and at other times, the effect lasts 1-2 
weeks, or even a month. 
The Biological vs. Psychological 
and Transpersonal Effects of Ketamine
As noted, some of the earlier ketamine studies attributed the anxiolytic and antidepressant post-
treatment effects to “psychedelic afterglow” following 
the induction of NOSC. Contrary to the earlier reports, 
most of the recent studies ignore the psychological effects 
of ketamine-induced altered states of consciousness and 
appear to largely dismiss these psychological phenomena, 
particularly those of a transpersonal quality which 
are presented mostly as an undesirable side-effect. For 
example, Arun Ravindran, psychiatry professor at the 
University of Toronto and chief of mood and anxiety 
disorders at Toronto’s Centre for Addiction and Mental 
Health, will be leading a study specifically exploring oral 
and intranasal routes of ketamine administration. In a 
recent interview with The New York Times (October 10, 
2014), Professor Rivandran was referring to ketamine-
induced psychological phenomenon as an unwanted 
side-effect that he called the “relaxed dissociated state.” 
 Virtually all scientific investigators who have 
recently published in this area present similar opinions 
in their published writings, and largely attribute the 
antidepressant effects of ketamine to its pharmacological 
properties to alter the glutamate system, which in turn 
modulates other systems such as dopamine (aan het Rot 
et al., 2010; Bjerre & Fontenay, 2010; DiazGranados 
et al., 2010; Glue et al., 2011; Ibrahim et al., 2012; 
Liebrenz et al., 2007, 2009; Murroughet et al., 2011, 
2012; Rasmussen et al., 2013; Rot et al., 2008; Zarate et 
al., 2006, 2012). This current biological theory proposes 
that, in addition to biochemical sub-types of depression 
caused by an “imbalance” of biogenic amines (serotonin, 
norepinephrine, and dopamine), there is also a separate 
sub-type of depression that biochemically mediates the 
same syndromic diagnosis of major depressive disorder due 
to an “imbalance” of glutamate (aan het Rot et al., 2010; 
Bjerre & Fontenay, 2010; Hashimoto, 2009; Ibrahim et 
al., 2012; Liebrenz et al., 2007; Machado-Vieira, Manji, 
& Zarate, 2009; Murrough et al., 2011; Rasmussen et al., 
2013; Rot et al., 2008; Scolnick, Popik, & Trullas, 2009; 
Zarate et al., 2006, 2012).
 There are complications with this theory. An 
existing NMDA receptor antagonist, memantine, was 
first developed in 1968 and has long been used as a 
neuro-protective agent and prescribed by some doctors 
for moderate-to-severe dementia. Like many other 
NMDA antagonists, memantine is a dissociative agent 
at above therapeutic doses (Morris & Wallach, 2014). 
It can even substitute for phencyclidine in rodent 
and primate drug discrimination studies (Parsons 
& Danysz, 1999). Although memantine has been 
associated in some studies with a modest decrease in 
the clinical deterioration of patients with moderate-to-
severe dementia (Rossi, 2006), it has been reported as 
having only an insignificant positive effect on mood 
in the treated patients (Areosa, Sherriff, & McShane, 
2005). There is still relatively little evidence of even a 
minimal effect on mild Alzheimer’s disease (Schneider, 
Dagerman, Higgins, & McShane, 2011). Zarate and his 
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team have also reported that memantine does not relieve 
depression (Brown, 2007). The claim that memantine 
would be effective in Alzheimer’s disease was rather 
surprising as it is well established that NMDA receptor 
blockade impairs memory rather than improving it (e.g., 
Collingridge, 1987). Ketamine users tend to report 
problems with their short-term memories rather than any 
improvement (Jansen, 2001; Morgan & Curran, 2012).
 Another available glutamate-modulating agent, 
riluzole (Rilutetek), a drug that inhibits glutamate 
release, does somewhat improve depression but no better 
than conventional antidepressants and with the same 
time delay (Sanacora et al., 2007; Zarate et al., 2004, 
2005). Riluzole was also researched in patients treated 
with ketamine in an attempt to sustain antidepressant 
effects. However, the studies failed to demonstrate any 
benefit over placebo in maintaining response to an IV 
ketamine infusion (aan het Rot et al., 2012; Brown, 
2007; Ibrahim et al., 2012; Mathew et al., 2010). 
 A recent study using sophisticated proton 
magnetic resonance spectroscopy has specifically 
investigated ketamine’s effects on glutamate brain levels 
in depressed patients but found no association between 
the antidepressant effects of ketamine and any significant 
changes in brain glutamate levels in both immediate 
(3 hours) and delayed (2 days) response to a ketamine 
administration (Valentine et al., 2011).
 Undoubtedly, ketamine has many direct and/
or indirect pharmacological effects on the human 
brain that may immediately improve the subject’s 
mood. These effects are multifactorial. In addition to 
affecting the glutamate system (similarly to alcohol), 
ketamine affects the dopamine system (similarly to 
NRIs and amphetamines), GABA system (similarly to 
benzodiazepines), serotonin system (similarly to SSRIs), 
mu opioid system (similarly to opiates), cannabinoid 
system (similarly to THC), and nitric system (similarly 
to nitrous oxide or “laughing gas”). All of the above 
compounds have been shown to rapidly generate anti-
anxiety and anti-depressant effects (especially when 
administered intravenously). The duration of their 
effects, however, has generally not much exceeded the 
pharmacological life of a particular compound and, it 
must be noted, its psychoactive metabolites which can be 
much longer.
 Approximately one third of the ketamine 
subjects did not maintain a remission of depressive 
symptoms for longer than 24 hours post-infusion. Two 
thirds of the subjects did maintain a remission lasting 
from 2-5 days to 1-2 weeks. Why would remission last 
longer than one day? One possibility is some persistence 
of the NMDA-receptor active metabolites, with 
variations between people in the rate of metabolism due 
to genetic and life-style differences (Jansen, 2001). There 
are other psychiatric treatments where the persistence of 
metabolites, sometimes for many weeks, is accepted as 
central to the mechanism of action. The antipsychotic 
drug haloperidol is a good example, with the active 
metabolite lasting in the blood for many weeks. Thus 
ceasing to take haloperidol rarely results in an immediate 
relapse of psychosis. 
 However, it is also possible that the so-called 
“relaxed dissociated state” is not an unwanted side-
effect, but is actually a cause of protracted remissions 
for psychological reasons. This may well prove to be 
the correct explanation. A recent study done by the 
Zarate group of investigators (Luckenbaugh et al., 2014) 
presented data from 108 treatment-resistant inpatients 
who met criteria for major depression or type I and II 
bipolar disorder and were given a sub-anesthetic ketamine 
infusion. The group examined whether dissociation 
experiences, measured by the Clinician-Administered 
Dissociative States Scale (CADSS), correlated with 
improvements in the Hamilton Depression Rating Scale 
(HDRS). The correlations’ analysis indicated that there 
was a significant association between increased CADSS 
scores and improvement in HDRS scores, while none of 
the other analyzed parameters significantly correlated 
to HDRS change. The study concluded that those 
patients with more dissociation are also those in whom 
ketamine has a greater antidepressant efficacy, while the 
patients who did not show the dissociation did not have 
antidepressant efficacy in the post-infusion period. 
 This paper resonates with the earlier ketamine 
studies attributing a post-treatment remission of anxiety 
and depression to the quality of NOSC experience. It may 
be that one third of the experimental ketamine subjects 
had an alcohol-like euphoric affect and their remission 
thus lasted for no longer than 24 hours post-infusion. 
Another one third of the subjects had an MDMA-like 
empathogenic experience, and their remission lasted for 
2-5 days post-infusion. The last one third of the patients 
had an OBE, and their remission lasted for 1-2 weeks 
and even longer. These odds are expected due to the 
fact that the standard 50 mg dose of ketamine used in 
the research subjects is located on the critical dosage 
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threshold between empathogenic and hallucinogenic 
responses, giving many subjects a 50% chance to have 
either an empathogenic or a hallucinogenic experience.
 It seems that reducing the experiences of 
ketamine to just being due to biological causes may 
be doing injustice to their psychological, and even 
transpersonal, effects. The following clinical case supports 
the theory that psychological factors are important: 
 
W was a 59 year-old Caucasian female, with a 
past history of sexual abuse (between ages 11 and 
17) and a life-long history of avoidant personality 
disorder (now re-classified as anxious personality 
disorder). She also developed scoliosis (a sideways 
curvature of the spine) during the growth spurt just 
before puberty and suffered from chronic pain since 
her mid-teens. In addition, she developed regular 
panic attacks, occurring 1-3 times a week, lasting 
from 10-20 minutes to several hours, since her late 
teens. W was raised as a Methodist, but converted 
to Hinduism at age 18, when she joined an ashram 
(a version of a contemporary monastery) in order to 
escape from her abuser (step-brother). W embraced 
a Yogini lifestyle and started practicing daily 
transcendental meditation, two times a day, 1 hour 
each sitting. 
At the age of 27, during an exceptionally 
long 10-day silent retreat, she spontaneously 
developed the Samadhi experience (ego-dissolving 
transcendental state of consciousness of mystical 
union with God) that lasted for several hours. W 
reported that after experiencing this state of “ecstatic 
bliss,” her anxious personality, chronic pain, and 
recurrent panic attacks were “gone in a blink of an 
eye.” Her remission lasted for 9 years until she was 
raped at the age of 36, which triggered a relapse of 
panic disorder, chronic pain disorder, and avoidant 
behavior. The rape also caused the onset of chronic 
depression. 
W continued meditating devotedly every single 
day and attended numerous silent retreats. However, 
she never had a mystical experience again. She had to 
start taking pharmaceuticals to control her chronic 
anxiety, depression, and pain, and she was treated 
with paroxetine, diazepam, and hydrocodone. The 
medications controlled her problems, but only 
partially. In addition, W slowly developed tolerance, 
which required a periodic upward adjustment of 
medication dose. By the time she requested ketamine 
treatment, she had to take daily 60 mg of paroxetine, 
80 mg of diazepam, and 120 mg of hydrocodone. 
Despite high doses of three pharmaceuticals, she 
continued having chronic depression (her Back 
Depression Inventory [BDI] score was 29), chronic 
anxiety (her Beck Anxiety Inventory [BAI] was 36) 
and chronic pain (rated 7 on 0-10 scale). 
 W considered undertaking KPP, after 
discovering a description of the EDT experience 
on Kolp’s website, in which she recognized her 
spontaneous Samadhi experience. She had no 
difficulties to prepare herself for the experience, as 
she already practiced a vegan lifestyle, meditated 
and exercised daily, contemplated on the nature of 
the Self and God much of her waking time, and 
used screen time only occasionally. For the last 10 
days of the preparation, she started practicing a 
juice fast in order to increase a chance of the EDT 
experience. 
The day before the administration of ketamine, 
W consulted her guru (a spiritual guide), who 
actively discouraged her from having the drug-
induced EDT experience. She was apparently told 
that the “Creator cannot be experienced through a 
narcotic, you should instead double your meditation 
time.” She accepted the guru’s instruction and 
requested to have only 50 mg of ketamine, since 
W believed that this dose represented a medically-
recommended dose that should be used as a 
therapeutic agent for the treatment of chronic 
“treatment-resistant” depression. Her therapist 
supported her wish, reminded W that she had a 
good chance of having the EDT experience due to 
her outstanding preparation, and instructed W “to 
close her eyes, start meditating, and surrender to 
whatever is to come.” W followed this instruction, 
positioned herself in a Savasana (“corpse”) pose, and 
then comfortably remained in the pose for the next 
2 hours. Upon her return from the journey she 
shared this experience:
As soon as I started breathing slowly and reciting 
my mantra my body started quickly relaxing and 
within 3 or 4 minutes the body became deeply 
relaxed and very comfortable. For the first time 
in the past 23 years the pain has disappeared. My 
mind was feeling very peaceful and calm … yet 
International Journal of Transpersonal Studies 118 Kolp et al.
the mind remained fully awake and alert. Again, 
for the first time in the past 23 years, the sad mood 
and persistent anxiety have gone away. At that 
point I stopped meditating and started enjoying the 
profound feelings of empathy, compassion and love 
for myself. The whole experience was full of joy and 
peace … I only regret that I stopped meditating 
and did not transcend to the Soul Consciousness 
and then to the God Consciousness… 
 W maintained a symptom-free remission for 
3.5 weeks and then developed a relapse of anxiety, 
followed by pain, and then depression. It was 
suggested that she undertake a second ketamine 
treatment. However, her spiritual guide persuaded 
her against it, pointing out that it may represent 
a drug-seeking behavior. The guru’s advice was 
“keep meditating.” At that point, W was started 
on phenelzine, 15 mg daily, with only a minimum 
response. After 4 weeks of treatment, the dose of 
phenelzine was increased to 30 mg daily, with a good 
response. W maintained a partial remission and her 
BDI score decreased to 17, the BAI score declined 
to 19, and her chronic pain level reduced to 3-4 on 
a scale of 10. She required two more adjustments of 
the phenelzine dose, to 45 mg 10 months later, and 
to 60 mg 17 months later. During her 2-year follow-
up, W continued maintaining a steady remission: 
her BDI score further decreased to 14, the BAI score 
remained 19, and the chronic pain level became 
stable at 3. 
As this case demonstrates, a spontaneous EDT experience 
can prolong the length of remission from depressive 
symptoms significantly longer than the best drug-
induced empathogenic experience. Although all NOSCs 
may contribute to accelerated healing, it seems that the 
EDT experience may have the most healing potential.
 The majority of Kolp’s patients with chronic 
treatment-resistant depression (approximately 90%), 
who requested ketamine pharmacotherapy with a sub-
psychedelic dose (50 mg IM), never had a trial with 
any MAOI antidepressants. Subsequently, Kolp began 
offering a trial with a MAOI antidepressant to all MAOI-
naïve patients and recommended starting the trial on the 
day following the IM ketamine administration. Nearly 
80% of the patients responded well, maintained a steady 
remission, and did not require a maintenance treatment 
with repeated IM administrations of ketamine.
Ketamine Addiction
The concerns of W’s guru about drug-seeking behavior in some ketamine users do have merit, as 
ketamine can generate strong effects on mood (feelings), 
cognition (thinking), and perception (imagery) that make 
some people want to use it repeatedly. However, initially 
both the FDA and the DEA accepted the Parke-Davis 
testimonials and apparently agreed that ketamine has no 
addictive properties. It was subsequently discovered that 
ketamine is a substance with very significant dependence 
potential for multiple reasons (Jansen, 2001). In fact, the 
68th edition of the Physicians’ Desk Reference specifically 
warns physicians that prolonged use of ketamine may 
lead to tolerance and drug dependence (PDR Network, 
2013).  Kolp found that more than two thirds of his 
ketamine patients wanted to have another empathogenic 
experience the following day and nearly one third of 
the patients wished to promptly repeat a psychedelic 
experience. 
 Ketamine has been available to hospital staff 
since late 1960s, and persons working in this context 
were amongst the first ones to personally test the drug’s 
empathogenic and psychedelic effects. The street use of 
ketamine hydrochloride solutions was first noted in San 
Francisco and Los Angeles circa 1971, while other forms 
of ketamine (powder and tablets) were first noticed on 
the street in 1974 (Ashley, 1978). Ketamine went under a 
variety of street names, including Special K and Vitamin 
K (Siegel, 1978). 
 One of the first reports describing the 
testimonials of non-prescription ketamine users came 
from Rumpf and his group of investigators (1969), whose 
subjects described ketamine hallucinations as “utopic,” 
“fantastic,” or “mysterious.” Only one out of their 18 
subjects considered the dream experiences normal 
and ordinary. The experience was termed pleasant by 
six subjects, unpleasant by eight, and neutral by four. 
Unexpectedly, Rumpf and colleagues reported that 
fully one third of the group (six subjects) had “true 
hallucinations” with the concomitant delusions that 
their dreams were not dreams, but, in point of fact, real 
events (Rumpf et al., 1969). 
 The first comprehensive study examining the 
patterns of ketamine addiction was done by Siegel 
(1978), who examined 23 subjects with recreational 
ketamine use. His sample included 13 injection users 
of ketamine and 10 intranasal ketamine users. Use 
of ketamine was primarily experimental or social in 
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nature, and the drug was viewed by users to be a potent 
yet safe hallucinogen with a short duration of action 
and few if any adverse effects. Ketamine users tended 
to titrate their use in order to achieve the desired effects 
of stimulation, dissociation, visual hallucinations, 
and transcendental experiences (Siegel, 1978).  When 
asked to rank all drugs in terms of general recreational 
preference, Siegel reported that intranasal users ranked 
cocaine first, while injection users ranked LSD first. 
The users consistently described ketamine in the 
following ways:
• Ketamine was perceived by users to be a safe, 
non-toxic, potent hallucinogen with a short 
duration of action and few adverse reactions.
• Ketamine was perceived by most users as the 
only hallucinogen that did not produce anxiety 
or fear reactions.
• Ketamine was considered to have unique 
euphoric-hallucinogenic properties that enabled 
a user to experience, with varying dosages, 
effects similar to either cocaine, amyl nitrite, 
phencyclidine, or LSD.
Ketamine users repeatedly sought and experienced 
the following desirable effects: floating sensations and 
dissociation (87%), stimulation (83%), hallucinations 
(78%), increased cognitive or mental associations 
(74%), euphoria (26%), and transcendental or religious 
experiences (17%). Despite the widespread beliefs among 
users about the lack of adverse reactions, a number of 
untoward effects were also reported, including ataxia 
(100%), slurring of speech (70%), dizziness (61%), mental 
confusion (35%), hyperexcitability (26%), unpleasant 
imagery (26%), blurring of vision (17%), negative 
hallucinations, or the inability to see things that were 
really there (17%), decreased sociability (17%), anxiety 
(13%), nausea (13%), insomnia (13%), and decreased 
sexual motivation (9%).
Siegel (1978) documented the specific long 
term effects, both positive and negative, resulting 
from ketamine use. Some ketamine users described a 
lasting elevation of mood (43%), deeper insights into 
self and others (35%) and positive changes in attitudes 
and personality (17%). Other ketamine users reported 
undesired long term effects including flashbacks (57%), 
attentional dysfunction (22%), and decreased sociability 
(9%). Overall, long-term effects appeared equally divided 
between positive and negative experiences.
 Ketamine was further popularized during the 
1970s by John Lilly, and to a lesser extent by astrologer 
Marcia Moore, who wrote books on the subject of self-
use of ketamine. Lilly published a book entitled The 
Scientist (1978) and Moore (together with her husband, 
Dr. Alltounian) published a book called Journeys into 
the Bright World (1978). Both books documented the 
unusual phenomenology of ketamine intoxication 
and prompted others to experiment with ketamine. 
Subsequently, many ketamine users in the “first wave” 
preferred ketamine for its psychedelic properties and 
administered it via IM self-injections.
The ketamine scene began changing during the 
late 1980s to early 1990s when lower doses of ketamine 
in pill and powder form, for intransal use, became more 
prevalent due to its empathogenic and stimulant effects 
at lower doses (Tori, 1996; NDIC Bulletin, 2004). 
Ketamine began appearing on the club, underground 
party, and rave scenes, being used together with or 
instead of ecstasy (MDMA), cocaine, and amphtamines. 
By the mid-1990s, ketamine had entered mainstream 
dance culture, and it remains a popular dance drug 
today (e.g., Joe-Laidler & Hunt, 2008).
Eventually, the U.S. Drug Enforcement 
Agency (DEA) became alarmed by this development 
and changed ketamine’s schedule in August of 1999, 
making it a controlled substance and moving the drug 
to Schedule III of the Controlled Substances Act of 
1970. Other countries have also done so, most recently 
India which had been a major source for the European 
market. India is now being replaced by China as the 
source. In 2000 the Hong Kong government placed 
ketamine in Schedule 1, a drastic measure in response 
to the recent rise in ketamine prevalence in East Asia. 
 As previously noted, the Russian government 
moved ketamine from Schedule III into Schedule II in 
2002 after ketamine became popular with Muscovite 
teenagers. In 2005, Canada re-classified ketamine as a 
Schedule I narcotic. The United Kingdom has moved 
ketamine from Class C to Class B in June of 2014, and 
controls were also tightened in New Zealand. These more 
recent changes were partly driven by the reports of binge 
non-medical ketamine use being linked with damage to 
the urinary system in some users. In addition, ketamine 
is in Category 3 under Mexico’s General Health Law. 
However, generic ketamine is still easily obtained in a 
“veteranaria farmacia” as “ketamina” for $15 to $20 a 
gram. According to a DEA report from 2004, over 80% 
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of ketamine seized in the United States at that time, ten 
years ago, was of Mexican origin (NDIC Bulletin, 2004). 
 Unlike phencyclidine, ketamine production 
is a complex and time-consuming process, making 
clandestine manufacturing of ketamine impractical. 
Meanwhile, ketamine is produced commercially in a 
number of countries, including (for example) the United 
States, Mexico, Columbia, China, India, Germany, 
and Belgium, where it may be diverted from legitimate 
sources. There have also been reports of industrial-scale 
illicit ketamine manufacture in China (UN Office on 
Drugs and Crime, 2010). 
Ketamine’s use as a recreational drug has been 
rising over the last 30 years (Copeland & Dillon, 2005; 
Dillon & Degenhardt, 2001; Jansen, 2000; Moore & 
Measham, 2008). Travis (2005) reported that ketamine 
was one of the six most common drugs for sale in 
UK cities. Stirling and colleagues (2008) published 
an update on recreational drug use in the United 
Kingdom and reported that 4% of the young adults 
in the study had tried ketamine at least once. Dillon, 
Copeland, and Jansen (2003) reported that about 1 in 3 
Australian respondents in a study of a drug user culture 
acknowledged the use of ketamine in the previous 12 
months. The 2006 National Survey on Drug Use and 
Health (NSDUH) reported that in the United States an 
estimated 2,300,000 persons aged 12 and older had used 
ketamine in their lifetime, and 203,000 were past year 
users (NSDUH Report, 2006). 
 There is a substantial popular literature describing 
ketamine dependence (e.g., Lilly, 1978; Sputz, 1989; Turner, 
1994). Ketamine recurrent binges can be sustained for 
many days and even several weeks. The medical literature 
has documented the same and the number of case studies 
is mounting (Ahmed & Petchkovsky, 1980; Hurt & 
Ritchie, 1994; Jansen, 1990a, 1990b, 2000, 2001; Kamaya 
& Krishna, 1987; Moore & Bostwick, 1999; Morgan & 
Curran, 2012; Soyka, Kripinsky, & Volki, 1993). The 
evidence from animal studies indicates that ketamine can 
form a dependence syndrome (Beardsley & Balster, 1987). 
The multiple problems related to dependence on ketamine, 
including education, relationships, employment, finances, 
and involvement in crime, have also been documented 
(Lim, 2003).
 In his private practice, Kolp has been handling 
ketamine as a Schedule II substance and has been 
repeatedly warning all patients that ketamine should 
never be used except under the direct supervision of a 
licensed physician. Instead of a ketamine maintenance 
treatment, Kolp encourages all MAOI-naïve patients 
to have a trial with MAOIs first, prior to commencing 
recurrent administrations of ketamine. To those 
patients who do not accept a trial with MAOI, or who 
failed it, Kolp offers a maintenance treatment with IM 
ketamine. However, he prefers limiting the frequency of 
ketamine IM administration to once every 4-6 weeks 
and never more frequently than once every 2 weeks. 
Kolp does not utilize oral, sublingual, or intranasal 
ketamine maintenance treatment for his patients in 
order to minimize the potential for ketamine abuse 
and dependence. The procedural parenteral approach 
(administering IM and IV ketamine in the office) would 
reduce the abuse and dependence potential by strictly 
controlling access to ketamine. In contrast, dispensing 
the drug to the patients (in-home oral, sublingual, and 
intranasal self-administration) would likely increase the 
abuse and dependence potential by increasing access 
to ketamine, and normalizing the use rather than this 
being a “special event.”
Potential Side-Effects 
of Ketamine Long-Term Treatment
The previously presented data on ketamine’s safety profile has been established for episodic and/or 
time-limited use of ketamine. Meanwhile, the side-
effects of acute and intermittent uses of a chemical 
substance and side-effects of the chronic use of the same 
compound may have two entirely different profiles. Once 
ketamine (and other similar glutamergic compounds) 
are sanctioned for use as oral anti-depressants, tens of 
millions of patients may start using this class of chemical 
compunds for an extended period of time. There may be 
value in comparing both the acute and chronic use of 
ketamine with another compound described as having 
some similar glutamergic properties. 
 Ethanol, similar to ketamine, has the capacity 
to block glutamate effects at the NMDA receptor, which 
contributes to ethanol’s acute behavioral effects and 
to the natural history and neuropathology of alcoholism 
(Tsai, Gastfriend, & Coyle, 1995). Ethanol decreases 
the NMDA-stimulated ion currents across the range 
of ethanol concentrations (from 5 to 100 mmol/L) 
that has been associated with human ethanol intoxi-
cation (Lovinger, White, & Weight, 1989; Nakanishi, 
1992; Simson et al., 1991). Meanwhile, chronic long-
term ethanol consumption increases the levels of 
NMDA receptors, up-regulates NMDA receptor-
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related binding, and produces cross-tolerance with 
other noncompetitive NMDA antagonists (Danysz, 
Jankowska, Glazewski, & Kostowski, 1992; Fidecka 
& Langwinski, 1989; Grant, Valverius, Hudspith, & 
Tabakoff, 1990; Iorio, Reinlib, Tabakoff, & Hoffman, 
1992; Trevisan et al., 1994).
 This increased NMDA receptor function 
produced by chronic long-term ethanol consumption 
contributes to alcohol withdrawal seizures (Grant et al., 
1990) and ethanol neurotoxic effects (Chandler et al., 1993). 
The NMDA antagonists ketamine and phencyclidine 
substitute for ethanol in preclinical drug discrimination 
paradigms (Grant & Colombo, 1993; Grant, Knisely, 
Tabakoff, Barrett, & Balster, 1991). This biochemical data 
may allow extrapolation of the effects of chronic long-term 
ethanol consumption to some possibly analogous effects of 
long-term chronic administration of ketamine and other 
related NMDA antagonist compounds. 
Ethanol has well-known anxiolytic and 
antidepressant effects with a robust onset of action and 
good anti-shock (neuro-protective) qualities when used 
sporadically. It usually only has a few serious side-effects 
when used episodically. The side-effects of acute ethanol use, 
however, are very different than the side-effects of chronic 
use. Ethanol, a known NMDA antagonist, is notorious 
for its ability to trigger apoptotic neurodegeneration when 
used chronically (Hoffman, Rabe, Moses, & Tabakoff, 
1989) and is a leading cause of dementia (Moriyama, 
Mimura, Kato, & Kashima, 2006). 
 A laboratory study conducted on primates 
suggested that chronic use of ketamine may induce 
neuronal cell death that is both apoptotic and necrotic in 
nature (Slikker et al., 2007). Other experimental data have 
confirmed this earlier study and documented that chronic 
ketamine exposure might produce irreversible deficits 
in brain functions due to neurotoxic effects, involving 
the activation of apoptotic pathways in the prefrontal 
cortex (Sun et al., 2014). A recent epidemiological study 
conducted on frequent and infrequent ketamine users 
reported that frequent ketamine use is associated with 
impairments in working memory, episodic memory, 
and aspects of executive function as well as reduced 
psychological wellbeing (Morgan, Muetzelfeldt, & 
Curran, 2009). The preliminary data are suggestive that 
once ketamine and other similar glutamergic compounds 
become available on the market as oral anti-depressants, 
chronic long-term use might cause neurodegenerative 
changes in the brain of some patients. 
The Future of Ketamine Psychotherapy 
from a Pharmacological Perspective
Although there is currently a lack of scientific data supporting a glutamate “imbalance” as a primary 
pathophysiological cause of major depression, there 
is a very short duration of post-ketamine remission of 
depression, and there are questions regarding the long-
term adverse effects of chronic use of ketamine, there is 
excitement in the psychiatric research community about 
the discovery of a new class of antidepressants with a 
mechanism that may be beyond the effects of biogenic 
amine neurotransmission.
 Professor Preskorn (2012) of Kansas University 
School of Medicine, who has been the principal 
investigator on over 250 clinical trials including drug 
development studies of all antidepressants marketed in 
the United States in the last 25 years (www.preskorn.
com), pointed out that all of the existing antidepressants 
are variations on the pharmacology of amphetamine, 
iproniazid (MAOI), and imipramine (TCA) and 
predicted that ketamine and related drugs could 
revolutionize psychiatry. Yale professors Ronald Duman 
and George Aghajanian, in a recent 2012 review of the 
ketamine research in Science, stated that the emerging 
ketamine treatment is the most important psychiatric 
discovery in recent times. 
 Nevertheless, it is very unlikely that ketamine 
will be developed for a mass market. It is an old drug 
that has long been off patent, so it is not currently 
profitable for drug manufacturers. The issue of some 
risk to the kidneys and bladder among some non-
medical users is not going away and affects perceptions, 
although the quantities involved and the circumstances 
for these people may differ markedly from its use for 
antidepressant, psychedelic, and other treatment 
regimens, and the risk in the latter situations will likely 
be minimal.  Furthermore, its reputation as an abused 
hallucinogen may now be too firmly embedded in the 
public awareness for any kind of marketing campaign of 
the sort commonly associated with antidepressants with 
billions of dollars at stake. 
 In addition, the accepted model for all available 
antidepressants is oral administration. Even ECT 
treatment involves both an anaesthetic (sometimes 
ketamine is used for this, and poses an important 
confounding variable in some ECT studies) along 
with the production of seizures with electricity. The 
intravenous and intramuscular routes of antidepressant 
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administration will severely limit the market size. The 
profit to be made from ketamine by the pharmaceutical 
industry from its use as an antidepressant thus appears 
to be somewhat limited. An aim of the present 
ketamine campaign will be to encourage research and 
development of similar NMDA receptor antagonist 
compounds that may be more profitable. Ketamine 
on its own has eight presently known metabolites, 
including esketamine, arketamine, bromoketamine, 
deschloroketamine, ethketamine, fluoroketamine, 
methoxetamine and methoxyketamine. Meanwhile, the 
entire arylcyclohexylamines group of presently known 
chemical compounds has nearly 60 various compounds. 
Reportedly, at least 30 other unscheduled analogs have 
been produced by clandestine sources.
 As of July 2014, Johnson & Johnson is 
developing a nasal spray formulation of esketamine 
for the management of treatment-resistant depression 
(Wijesinghe, 2014). Esketamine (a.k.a. (S)-ketamine or 
S(+)-ketamine) is the S(+) enantiomer of ketamine and 
twice as potent as racemic ketamine. A Phase 1 clinical 
trial of intranasal esketamine is sponsored by a Johnson 
& Johnson subsidiary, Janssen Pharmaceutical Research 
& Development, LLC. This company is conducting 
a clinical trial with 58 participants in Belgium; the 
purpose of this study is to assess the efficacy and dose 
response of intranasal esketamine (14 mg, 28 mg, 56 mg, 
and 84 mg) compared with placebo (clinicaltrials.gov/
show/NCT01998958).
 Another privately held biopharmaceutical 
company, Naurex Inc., has recently announced that 
it has successfully completed a Phase 2b clinical study 
of GLYX-13, the company’s lead compound (www.
naurex.com). The FDA has already granted Fast Track 
Designation to the research and development of this 
compound. The company also reported that it initiated a 
Phase 2a study of another orally active agent, NRX-1074, 
after collecting positive results from a recently completed 
Phase 1 study of the NRX-1074 drug. Both compounds 
are NMDA receptor antagonists. However, their 
specifics are unknown. Krystal, who may be one of the 
most powerful figures today in biological psychiatry, has 
endorsed research and development of both compounds, 
and Preskorn is a study investigator (www.naurex.com).
 Cerecor Inc., a Maryland-based biopharma-
ceutical company, is also in the process of developing 
a new antidepressant drug, CERC-301 (formerly 
known as MK-0657), as a therapy for TRD. The drug 
is a selective NMDA receptor antagonist and an orally-
active compound (Ibrahim et al., 2012). The company 
has initiated phase II clinical trials in November of 2013 
and this study has received Fast Track Designation from 
the FDA for TRD (www.cerecor.com).
 AstraZeneca, PLC (AZN) is studying another 
NMDA receptor antagonist, lanicemine (Wijesinghe, 
2014). Lanicemine was originally developed as a 
neuroprotective agent and then was redeveloped as 
an antidepressant following the report of Zarate and 
colleagues (2012), who documented that lanicemine 
has potent antidepressant effects similar to ketamine. 
However, the drug is claimed to have little or no 
psychotomimetic side effects (Zarate et al., 2012). 
 Although ketamine itself will probably not 
become the next generation of anti-depressants, 
it seems that numerous other members of the 
arylcyclohexylamines class will be presented for this 
purpose, and probably also presented as the next 
generation of anti-anxiety drugs, mood-stabilizers, 
and procognitive agents. Their impact on the urinary 
system will need to be assessed where long-term 
daily use is planned. It remains to be seen whether 
the next generation of glutamate-antagonist based 
pharmaceuticals will result in a growth of addiction to 
those which are psychoactive arylcyclohexylamines. 
 In addition to this flurry of activity to develop 
psycho-pharmacological applications of ketamine, 
especially in ways that can yield profits, there remains 
its psychological and transpersonal healing potential. 
Our position is that these offer its greatest likelihood 
of benefit, rather than through ketamine’s biological 
application.
Conclusion
Ketamine is a potent substance that offers much promise for alleviating suffering due to mental 
health issues, but it also poses considerable danger when it 
is misused.  As a psychiatric medication, ketamine offers 
a wide range of applications, from mild doses alleviating 
depression (at least in the short-term) to psychedelic 
dosages offering the possibility of transpersonal healing. 
The fact that ketamine is the only psychedelic that 
can legally be prescribed in the United States makes it 
unique at this time, and we encourage its responsible use 
within medical contexts for providing access to deep and 
profound healing experiences that may be difficult, if not 
impossible, for many to achieve without the aid of such 
a substance.    
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 We hope that ketamine will remain legally 
available for clinical applications and scientific research, 
including for the field of psychedelic psychotherapy. 
The current interest in ketamine may eventually 
bring psychedelic psychotherapy somewhat closer to 
the mainstream of psychiatry and psychology. Those 
dismissive of its spiritual component, who are inclined 
to consider this as “flakey,” should bear in mind that 
the most successful and cost-effective treatment for 
alcohol dependence remains the 12-step programs, such 
as Alcoholics Anonymous (The Fellowship; Alcoholics 
Anonymous World Services, 1984), and of course the 
spiritual component lies at the very heart of this approach 
(Corrington, 1989; Nathan, 1986). Spirituality retains a 
place in contemporary psychiatry. It is not so long ago 
that the Spirituality Special Interest Group became one 
of the nine Special Interest Groups at the Royal College 
of Psychiatry in London, and interest continues to grow. 
It would be difficult to argue that all of these psychiatrists 
are part of a lunatic fringe. 
 The United States is a country in which the 
overwhelming majority of the population has some 
spiritual beliefs. When one considers the high morbidity 
and mortality from disorders such as alcohol dependence 
and depression, it seems foolish to neglect all of the 
opportunities for treatment which this circumstance 
may offer. From a contemporary perspective, KPP is 
less drastic than some of its alternatives, such as ECT 
used for TRD and for which ketamine is sometimes 
used as an anaesthetic (and may even be the source 
of much of ECT’s purported effectiveness). It may be 
time for a cultural shift in perceptions. With billions 
of dollars at stake, it is understandable that some vested 
interests may directly and/or indirectly lobby to oppose 
any shift away from the culture of taking daily tablets 
(or perhaps nasal sprays) and the use of ECT as the 
ultimate psychiatric treatment. However, if protocols 
develop which combine innovative methods, such as 
KPP with ongoing maintenance alongside conventional 
medicines as “standard practice,” some of the profit-
based opposition may eventually lessen. Likewise, 
opposition from both conservative factions that might 
oppose any substance that can be seen as generating a 
“high,” as well as by more spiritually liberal factions that 
might denigrate such substances as less valid than using 
so-called “natural” approaches (e.g., meditation), would 
have to be confronted in the face of the tremendous 
suffering that KPP could alleviate.
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